Document:

<PAGE>
                                                                  EXECUTION COPY

================================================================================

                                ATS MEDICAL, INC.

                                 as the Company

                                       and

                                     BUYERS,

                                as defined herein

                          SECURITIES PURCHASE AGREEMENT

                           Dated as of October 6, 2005

                      6% Convertible Senior Notes due 2025
                      and Warrants to Purchase Common Stock

================================================================================
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            Page
                                                                            ----
<S>                                                                         <C>
SECTION 1. PURCHASE AND SALE OF NOTES....................................     2
SECTION 2. BUYER'S REPRESENTATIONS AND WARRANTIES........................     4
SECTION 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.................     8
SECTION 4. COVENANTS.....................................................    18
SECTION 5. TRANSFER AGENT INSTRUCTIONS...................................    23
SECTION 6. CONDITIONS TO THE COMPANY'S OBLIGATION TO CLOSE...............    23
SECTION 7. CONDITIONS TO EACH BUYER'S OBLIGATION TO PURCHASE.............    24
SECTION 8. INDEMNIFICATION...............................................    26
SECTION 9. MISCELLANEOUS.................................................    27
</TABLE>

                                    SCHEDULES

<TABLE>
<S>               <C>
Schedule A......  Company Wire Instructions
Schedule 3(a)...  Subsidiaries
Schedule 4(p)...  Buyers Electing Section 4(p) Treatment
</TABLE>

                                    EXHIBITS

<TABLE>
<S>               <C>
Exhibit A......   Schedule of Buyers
Exhibit B......   Form of Indenture
Exhibit C......   Form of Warrant Agent Agreement
Exhibit D......   Schedule of Fees
Exhibit E......   Form of Registration Rights Agreement
Exhibit F......   Form of Irrevocable Transfer Agent Instructions
Exhibit G......   Form of Company Counsel Opinion
</TABLE>

                                        i
<PAGE>
                          SECURITIES PURCHASE AGREEMENT

     THIS SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of October
6, 2005, by and among ATS Medical, Inc., a Minnesota corporation (the
"Company"), and the Buyers listed on the Schedule of Buyers attached hereto as
Exhibit A (individually, a "Buyer" and, collectively, the "Buyers").

     THE PARTIES TO THIS AGREEMENT enter into this Agreement on the basis of the
following facts, intentions and understandings:

     A. In accordance with the terms and conditions of this Agreement, the
Company has agreed to issue and sell, and the Buyers have severally agreed to
purchase in the aggregate, (i) Nineteen Million United States Dollars
($19,000,000) principal amount of the Company's 6% Convertible Senior Notes due
2025 (such Convertible Senior Notes, substantially in the form attached as
Exhibit A to the Indenture (as defined below), as such form of Note may be
amended, modified or supplemented from time to time in accordance with the terms
thereof, the "Initial Notes"), which shall be convertible into shares of the
common stock, $0.01 par value per share (the "Common Stock"), of the Company (as
converted, the "Initial Conversion Shares"), and (ii) Warrants (such Warrants,
substantially in the form attached as Exhibit A to the Warrant Agent Agreement
(as defined below), as such Form of Warrant may be amended, modified or
supplemented from time to time in accordance with the terms thereof, the
"Initial Warrants") to purchase 1,140,000 shares of Common Stock (as exercised,
the "Initial Warrant Shares"). The Initial Notes will be issued pursuant to an
Indenture, dated as of October 7, 2005 (the "Indenture") by and between the
Company and Wells Fargo Bank, National Association, as trustee (the "Trustee"),
substantially in the form attached hereto as Exhibit B. The Initial Warrants
will be issued pursuant to a Warrant Agent Agreement, dated as of October 7,
2005 (the "Warrant Agent Agreement") by and between the Company and Wells Fargo
Bank, National Association, as warrant agent (the "Warrant Agent"),
substantially in the form attached hereto as Exhibit C.

     B. Contemporaneously with the execution and delivery of this Agreement, the
parties hereto are executing and delivering a Registration Rights Agreement
substantially in the form attached hereto as Exhibit E (as the same may be
amended, modified or supplemented from time to time in accordance with the terms
thereof, the "Registration Rights Agreement") pursuant to which the Company has
agreed to provide the Buyers with the benefit of certain registration rights
under the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder (the "Securities Act") and applicable state securities
laws, on the terms and subject to the conditions set forth therein.

     NOW THEREFORE, in consideration of the promises and the mutual covenants
contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company and each of the Buyers
hereby agree as follows:
<PAGE>
     SECTION 1. PURCHASE AND SALE OF NOTES.

     (a) Purchase of Notes and Warrants.

     (1) Subject to the satisfaction (or waiver, to the extent permitted by
applicable law) of the conditions set forth in Sections 6 and 7 of this
Agreement, the Company shall issue and sell to each Buyer, and each Buyer
severally and not jointly agrees to purchase from the Company, the respective
principal amount of Initial Notes, together with the related Initial Warrants,
set forth opposite such Buyer's name on the Schedule of Buyers attached hereto
as Exhibit A (the "Initial Closing"). The Company shall issue to each Buyer One
Thousand United States Dollars ($1,000) principal amount of Initial Notes and
Initial Warrants to purchase approximately 60 Initial Warrant Shares for each
One Thousand United States Dollars ($1,000) tendered by each such Buyer.

     (2) The Company hereby grants the Buyers an option to purchase, severally
and not jointly, (A) up to an additional Four Million Seven Hundred Fifty
Thousand United States Dollars ($4,750,000) aggregate principal amount of 6%
Convertible Senior Notes due 2025 (such Convertible Senior Notes, substantially
in the form attached as Exhibit A to the Indenture, as such form of Note may be
amended, modified or supplemented from time to time in accordance with the terms
thereof, the "Additional Notes" and, together with the Initial Notes, the
"Notes"), which shall be convertible into shares of Common Stock (as converted,
the "Additional Conversion Shares"), and (B) Warrants (such Warrants,
substantially in the form attached as Exhibit A to the Warrant Agent Agreement,
as such Form of Warrant may be amended, modified or supplemented from time to
time in accordance with the terms thereof, the "Additional Warrants" and,
together with the Initial Warrants, the "Warrants") to purchase 285,000 shares
of Common Stock (as exercised, the "Additional Warrant Shares"). The Additional
Notes will be issued pursuant to the Indenture, and the Additional Warrants will
be issued pursuant to the Warrant Agent Agreement. For purposes of this
Agreement, the term "Conversion Shares" refers to Initial Conversion Shares and
Additional Conversion Shares, collectively, and the term "Warrant Shares" refers
to Initial Warrant Shares and Additional Warrant Shares, collectively.

     Each Buyer may exercise this right at any time between the Closing Date
(October 7, 2005) and the one hundred and twentieth (120th) calendar day
following such Closing Date (such period of time being the "Option Period") by
giving written notice of election to exercise this option (such notice of
election being the "Option Exercise Notice") prior to 5:00 p.m., Minneapolis,
Minnesota local time, on any Business Day during such Option Period. Any Option
Exercise Notice shall specify the principal amount of Additional Notes and the
number of Additional Warrants to be purchased by the Buyer; provided that any
Buyer may not purchase more than its pro rata portion of Additional Notes and
Additional Warrants, based on the proportion of the principal amount of the
Initial Notes set forth opposite the name of such Buyer on the Schedule of
Buyers attached hereto as Exhibit A to the aggregate principal amount of Initial
Notes issued on the Closing Date. The purchase price of the Additional Notes and
the Additional Warrants shall be the aggregate principal amount of the
Additional Notes to be purchased plus accrued interest on the Additional Notes
from the Closing Date through the Option Closing Date.

                                        2
<PAGE>
     (b) The Initial Closing and the Option Closing.

     (1) The date and time of the Initial Closing (the "Closing Date") shall be
10:00 a.m., Minneapolis, Minnesota local time, on October 7, 2005, subject to
the satisfaction (or waiver, to the extent permitted by applicable law) of the
conditions set forth in Sections 6 and 7 of this Agreement. The Initial Closing
shall occur on the Closing Date at the offices of Dorsey & Whitney LLP, 50 South
Sixth Street, Suite 1500, Minneapolis, Minnesota 55402.

     (2) The payment for and delivery of the Additional Notes and the Additional
Warrants for which the Buyers have delivered timely Option Exercise Notices (the
"Option Closing") shall occur before 11:00 a.m., Minneapolis, Minnesota local
time, three (3) Business Days after the later of (A) the expiration of the
Option Period and (B) the Postponement Termination Date, if any (the "Option
Closing Date"). Notwithstanding anything to the contrary herein, the Company may
delay the Option Closing for a period not to exceed sixty (60) days (the
"Postponement Period") if, in the Company's good faith judgment, the disclosure
of any material non-public information or pending development concerning the
Company of which the Company is aware at the end of the Option Exercise Period
and/or on the original date set for the Option Closing Date, is determined to
not be in the best interests of the Company; provided, however, that the Company
shall promptly notify the Buyers in writing (the "Postponement Notice") of (A)
the existence of such material non-public information or pending development
giving rise to a Postponement Period (provided that the Company shall not
disclose the content of such material non-public information or pending
development to such Buyers) and (B) the date on which the Postponement Period is
scheduled to end. For purposes of determining the length of the Postponement
Period, which may not exceed sixty (60) days, the Postponement Period shall be
deemed to begin on and include the original date set for the Option Closing Date
and shall end on and include the earlier of (x) the date stated in the
Postponement Notice as the end of the Postponement Period or (y) to the extent
considered appropriate by the Company in its sole discretion, any other date as
to which the Company may advise the Buyers in writing (such notice being the
"Postponement Termination Notice") after the Company's provision of the notices
described above (the "Postponement Termination Date"); provided that any Buyer
which has submitted an Option Exercise Notice may withdraw its Option Exercise
Notice by notifying the Company in writing of such Buyer's withdrawal at any
time after the delivery of the Postponement Notice by the Company but before
5:00 p.m., Minneapolis, Minnesota local time, on the date which is one (1)
Business Day after the Postponement Termination Date.

     (c) Form of Payment. On the Closing Date and the Option Closing Date, if
any, (i) each Buyer shall pay the Company for the Notes and the related Warrants
to be issued and sold to such Buyer on the Closing Date, or the Option Closing
Date, as the case may be, by wire transfer of immediately available funds in
accordance with the Company's written wire instructions attached hereto on
Schedule A, (ii) the Company shall reimburse each Buyer for its reasonable
expenses to the extent required by Section 4(i) of this Agreement, and (iii) the
Company shall issue to each Buyer properly authenticated Notes (in the
denominations of not less than One Thousand United States Dollars ($1,000) as
such Buyer shall reasonably request) representing the principal amount of Notes
which such Buyer is then purchasing hereunder, along with Warrants representing
the related number of Warrant Shares, duly executed on behalf of the Company and
registered in the name of such Buyer, provided, that Notes eligible for services
through The Depository Trust Company ("DTC") shall be issued, countersigned,

                                        3
<PAGE>
registered and delivered in global certificate form through the facilities at
DTC in such names and denominations as each Buyer shall specify.

     SECTION 2. BUYER'S REPRESENTATIONS AND WARRANTIES. Each Buyer represents
and warrants to the Company with respect to only itself that as of the date
hereof:

     (a) Investment Purpose. Such Buyer is acquiring the Notes and the Warrants
for its own account and not with a view towards, or for resale in connection
with, the public sale or distribution thereof, except pursuant to sales
registered or exempted from registration under the Securities Act; provided,
however, that by making the representations herein, such Buyer does not agree to
hold any of the Notes, the Conversion Shares, the Warrants and the Warrant
Shares (collectively, the "Securities") for any minimum or other specific term
and reserves the right to dispose of the Securities at any time; provided,
further, that such disposition shall be in accordance with or pursuant to a
registration statement or an exemption under the Securities Act.

     (b) Accredited Investor and Qualified Institutional Buyer Status. Such
Buyer is an "accredited investor" as that term is defined in Rule 501(a) of
Regulation D under the Securities Act and a "qualified institutional buyer" as
that term is defined in Rule 144A(a) under the Securities Act as of the date of
this Agreement and was not organized for the specific purpose of acquiring the
Securities.

     (c) Reliance on Exemptions. Such Buyer understands that the Securities are
being offered and sold to it in reliance on specific exemptions from the
registration requirements of the United States federal and state securities laws
and that the Company is relying upon the truth and accuracy of, and such Buyer's
compliance with, the representations, warranties, agreements, acknowledgments
and understandings of such Buyer set forth herein and in the applicable Note or
Warrant in order to determine the availability of such exemptions and the
eligibility of such Buyer to acquire the Securities.

     (d) Information. Such Buyer believes it (i) has been furnished with or
believes it has had full access to all of the information that it considers
necessary or appropriate for deciding whether to purchase the Securities,
including a copy of the Confidential Private Placement Memorandum, (ii) has had
an opportunity to ask questions and receive answers from the Company regarding
the terms and conditions of the offering of the Securities, (iii) can bear the
economic risk of a total loss of its investment in the Securities and (iv) has
such knowledge and experience in business and financial matters so as to enable
it to understand the risks of and form an investment decision with respect to
its investment in the Securities. Neither such inquiries nor any other due
diligence investigations conducted by such Buyer or its advisors, if any, or its
representatives shall limit, modify, amend or affect the Company's
representations and warranties contained in this Agreement or any other
Transaction Document and the Buyer's right to rely thereon.

     (e) No Governmental Review. Such Buyer understands that no United States
federal or state agency or any other government or governmental agency has
passed on or made any recommendation or endorsement of the Securities or the
fairness or suitability of the investment in the Securities nor have such
authorities passed upon or endorsed the merits of the offering of the
Securities.

                                        4
<PAGE>
     (f) Transfer or Resale. Such Buyer understands that, except as provided in
the Registration Rights Agreement, the Securities have not been registered under
the Securities Act or any state securities laws, and may not be offered for
sale, sold, assigned or transferred without registration under the Securities
Act or an exemption therefrom and that, in the absence of an effective
registration statement under the Securities Act, such Securities may only be
sold under certain circumstances as set forth in the Securities Act. In that
connection, such Buyer is aware of Rule 144 under the Securities Act and the
restrictions imposed thereby.

     (g) Legends.

     (1) Such Buyer understands that, until the expiration of the holding period
applicable to sales thereof under Rule 144(k) (or any successor provision), any
certificate evidencing such Notes and any certificate evidencing such Warrants
(and all securities issued in exchange therefor or in substitution thereof,
other than Common Stock, if any, issued upon conversion thereof (in the case of
a Note) or upon exercise thereof (in the case of a Warrant), which shall bear
the legend set forth in Section 2(g)(2) of this Agreement, if applicable) shall
bear a legend in substantially the following form:

     THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
     UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR
     APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR
     SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE
     REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT AND
     APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION THEREFROM.

     The legend set forth above shall be removed and the Company shall issue a
new Note or Warrant, as appropriate, of like tenor and aggregate principal
amount or number of shares, as appropriate, and which shall not bear the
restrictive legends required by this Section 2(g)(1), (i) if such Notes or
Warrants, as appropriate, are registered for resale under the Securities Act and
are transferred or sold pursuant to such registration, (ii) if, in connection
with a sale transaction, such holder provides the Company, if so requested, with
an opinion of counsel reasonably acceptable to the Company to the effect that
such sale, assignment or transfer of the Notes or Warrants, as appropriate, may
be made without registration under the Securities Act, or (iii) upon expiration
of the two-year period under Rule 144(k) of the Securities Act (or any successor
rule) if the holder of the Securities has not been an "affiliate" (as defined in
Rule 501(b) of Regulation D under the Securities Act) during the preceding three
(3) months.

     (2) Such Buyer understands that any stock certificate representing
Conversion Shares or Warrant Shares shall bear a legend in substantially the
following form (unless (i) such Conversion Shares or Warrant Shares have been
transferred or sold pursuant to an effective registration statement, (ii) such
Conversion Shares or Warrant Shares, as appropriate, have been transferred or
sold pursuant to the exemption from registration provided by Rule 144 under the
Securities Act, (iii) such Conversion Shares or Warrant Shares, as appropriate,
may be transferred pursuant to Rule 144(k) under the Securities Act, or (iv)
unless otherwise agreed by the Company in writing with written notice to the
transfer agent):

                                        5
<PAGE>
     THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
     UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR
     APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR
     SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE
     REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT AND
     APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION THEREFROM.

     The legend set forth above shall be removed and the Company shall issue the
relevant Securities without such legends to the holder of the Securities upon
which it is stamped, (i) if such Securities are registered for resale under the
Securities Act and are transferred or sold pursuant to such registration, (ii)
if, in connection with a sale transaction, such holder provides the Company, if
so requested, with an opinion of counsel reasonably acceptable to the Company to
the effect that a public sale, assignment or transfer of the Securities may be
made without registration under the Securities Act, or (iii) upon expiration of
the two-year period under Rule 144(k) of the Securities Act (or any successor
rule) if the holder of the Securities has not been an "affiliate" (as defined in
Rule 501(b) of Regulation D under the Securities Act) during the preceding three
(3) months.

     Notwithstanding the foregoing, the Company agrees that it will issue stock
certificates representing Conversion Shares or Warrant Shares without the
legends shown above in this Section 2(g)(2) if, at the time of such issuance,
(i) such Shares are registered for resale under the Securities Act pursuant to
an effective registration statement filed by the Company, and (ii) the Buyer to
whom such Shares are to be issued has provided representations to the Company,
in a form reasonably acceptable to the Company, to the effect that such Shares
will only be sold either in accordance with the requirements for sale pursuant
to such registration statement, including the prospectus delivery requirement,
or in accordance with the provisions of Rule 144.

     (3) Such Buyer understands that, in the event Rule 144(k) as promulgated
under the Securities Act (or any successor rule) is amended to change the
two-year or three-month periods under Rule 144(k) (or the corresponding periods
under any successor rule), (i) each reference in Sections 2(g)(1) and 2(g)(2) of
this Agreement to "two (2) years" or the "two-year period" and to "three (3)
months" shall be deemed for all purposes of this Agreement to be references to
such changed period or periods, and (ii) all corresponding references in the
Notes and Warrants shall be deemed for all purposes to be references to the
changed period or periods, provided that such changes shall not become effective
if they are otherwise prohibited by, or would otherwise cause a violation of,
the then-applicable federal securities laws.

     (h) Authorization; Enforcement; Validity. This Agreement and the
Registration Rights Agreement have been duly and validly authorized, executed
and delivered on behalf of such Buyer and are valid and binding agreements of
such Buyer enforceable against such Buyer in accordance with their terms,
subject as to enforceability to general principles of equity and to applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation and other
similar laws relating to, or affecting generally, the enforcement of applicable
creditors' rights and remedies.

                                        6
<PAGE>
     (i) Residency. Such Buyer is a resident of that country or state specified
in its address on the Schedule of Buyers attached hereto as Exhibit A.

     (j) No Conflicts. The execution and performance of this Agreement and the
Registration Rights Agreement do not conflict with any agreement to which such
Buyer is a party or is bound thereby, any court order or judgment addressed to
such Buyer, or the constituent documents of such Buyer.

     (k) Conversion/Exercise Limitation. (A) Subject to Buyer's election on the
signature pages hereto to be governed by this Section 2(k)(A), each Buyer hereby
agrees that in no event will it convert any of the Notes or exercise of any of
the Warrants in excess of the number of such Notes or Warrants, upon the
conversion or exercise of which (x) the number of shares of Common Stock
beneficially owned by such Buyer (other than the shares which would otherwise be
deemed beneficially owned except for being subject to a limitation on conversion
or exercise analogous to the limitation contained in this Section 2(k)(A)) plus
(y) the number of shares of Common Stock issuable upon the conversion of such
Notes and the exercise of such Warrants, would be equal to or exceed 9.99% of
the number of shares of Common Stock then issued and outstanding (after giving
effect to such conversion or exercise), it being the intent of the Company and
the Buyers that no Buyer electing to be governed by this Section 2(k)(A) be
deemed at any time to have the power to vote or dispose of greater than 9.99% of
the number of shares of Common Stock issued and outstanding. As used herein,
beneficial ownership shall be determined in accordance with Section 13(d) of the
Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder (the "Exchange Act"). To the extent that the limitation
contained in this Section 2(k)(A) applies (and without limiting any rights the
Company may otherwise have), the Company may rely on the Buyer's determination
of whether the Notes are convertible and whether the Warrants are exercisable
pursuant to the terms hereof, the Company having no obligation whatsoever to
verify or confirm the accuracy of such determination, and the submission of the
Conversion Notice (as that term is defined in the Note) or the Exercise Notice
(as that term is defined in the Warrant) by the Buyer shall be deemed to be the
Buyer's representation that the Notes or the Warrants specified therein are
convertible or exercisable pursuant to the terms hereof. Nothing contained
herein shall be deemed to restrict the right of a Buyer to convert the Notes or
exercise the Warrants at such time as the conversion or exercise thereof will
not violate the provisions of this Section 2(k)(A). Notwithstanding anything to
the contrary, this Section 2(k)(A) shall not apply to a Buyer who has elected to
opt out of the application of this Section by so indicating in the signature
page.

     (B) Subject to Buyer's election on the signature pages hereto to be
governed by this Section 2(k)(B), each Buyer hereby agrees that in no event will
it convert any of the Notes or exercise any of the Warrants in excess of the
number of such Notes or Warrants, upon the conversion or exercise of which (x)
the number of shares of Common Stock beneficially owned by such Buyer (other
than the shares which would otherwise be deemed beneficially owned except for
being subject to a limitation on conversion or exercise analogous to the
limitation contained in this Section 2(k)(B)) plus (y) the number of shares of
Common Stock issuable upon the conversion of such Notes and the exercise of the
Warrants, would be equal to or exceed 4.99% of the number of shares of Common
Stock then issued and outstanding (after giving effect to such conversion), it
being the intent of the Company and the Buyers that no Buyer electing to be
governed by this Section 2(k)(B) be deemed at any time to have the power to vote
or dispose

                                        7
<PAGE>
of greater than 4.99% of the number of shares of Common Stock issued and
outstanding. As used herein, beneficial ownership shall be determined in
accordance with Section 13(d) of the Exchange Act. To the extent that the
limitation contained in this Section 2(k)(B) applies (and without limiting any
rights the Company may otherwise have), the Company may rely on the Buyer's
determination of whether the Notes are convertible and whether the Warrants are
exercisable pursuant to the terms hereof, the Company having no obligation
whatsoever to verify or confirm the accuracy of such determination, and the
submission of the Conversion Notice (as that term is defined in the Note) or the
Exercise Notice (as that term is defined in the Warrant) by the Buyer shall be
deemed to be the Buyer's representation that the Notes or the Warrants specified
therein are convertible or exercisable pursuant to the terms hereof. Nothing
contained herein shall be deemed to restrict the right of a Buyer to convert the
Notes or exercise the Warrants at such time as the conversion or exercise
thereof will not violate the provisions of this Section 2(k)(B). Notwithstanding
anything to the contrary, this Section 2(k)(B) shall not apply to a Buyer who
has elected to opt out of the application of this Section by so indicating in
the signature page.

     (l) Additional Acknowledgement. Each Buyer acknowledges that it has
independently evaluated the merits of the transactions contemplated by this
Agreement, the Indenture, the Warrant Agent Agreement, the Notes, the
Registration Rights Agreement and the Warrants, that it has independently
determined to enter into the transactions contemplated hereby and thereby, that
it is not relying on any advice from or evaluation by any other Buyer, and that
it is not acting in concert with any other Buyer in purchasing the Securities
offered hereunder. The Buyers and, to its knowledge, the Company agree that the
Buyers have not taken any actions that would cause such Buyers to be deemed as
members of a "group" for purposes of Section 13(d) of the Exchange Act.

     The Buyer's representations and warranties made in this Section 2 are made
solely for the purpose of permitting the Company to make a determination that
the offer and sale of the Notes and Warrants pursuant to this Agreement complies
with applicable U.S. federal and state securities laws and not for any other
purpose. Accordingly, the Company shall not rely on such representations and
warranties for any other purpose.

     SECTION 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company
represents and warrants to the Placement Agent and each of the Buyers that as of
the date hereof:

     (a) Organization and Qualification. The Company and its Subsidiaries (as
defined below) are corporations, partnerships or limited liability companies
duly organized and validly existing in good standing under the laws of the
jurisdiction in which they are incorporated or organized, and have the requisite
corporate, limited liability company or partnership power and authorization to
own their properties and to carry on their business as now being conducted.
Copies of the Company's Articles of Incorporation and Bylaws, and all amendments
thereto, have been filed as exhibits to the Company's SEC Documents (as defined
in Section 3(f) of this Agreement), are in full effect and have not been
modified. Each of the Company and its Subsidiaries is duly qualified as a
foreign corporation, partnership or limited liability company to do business and
is in good standing in every jurisdiction in which its ownership of property or
the nature of the business conducted and proposed to be conducted by it makes
such qualification necessary, except to the extent that the failure to be so
qualified or be in good standing would not

                                        8
<PAGE>
have a Material Adverse Effect. As used in this Agreement, "Material Adverse
Effect" means any material adverse effect on the business, properties, assets,
operations, results of operations or financial condition of the Company and its
Subsidiaries, taken as a whole, other than any effect relating to or resulting
from (i) the economy or the financial markets in general, (ii) the industry in
which the Company and its Subsidiaries operate in general, or (iii) the
announcement of the transaction contemplated hereby. "Subsidiary" means any
entity in which the Company, directly or indirectly, owns or controls a majority
of the ordinary voting power, capital stock or other equity or similar
interests. The Company's "Subsidiaries" are set forth on Schedule 3(a), and the
Company's "Significant Subsidiaries" are separately identified on that Schedule.

     (b) Authorization; Enforcement; Validity. The Company has the requisite
corporate power and authority to enter into and perform its obligations under
this Agreement, the Indenture, the Warrant Agent Agreement, the Notes, the
Warrants, the Registration Rights Agreement, the Irrevocable Transfer Agent
Instructions (as defined in Section 5 of this Agreement) and each of the other
agreements entered into by the parties hereto in connection with the
transactions contemplated by this Agreement (collectively, the "Transaction
Documents"), and to issue and sell the Securities in accordance with the terms
hereof and thereof. The execution and delivery of the Transaction Documents by
the Company and the consummation by it of the transactions contemplated hereby
and thereby, including, without limitation, the issuance and repayment of the
Notes, the reservation for issuance and the issuance of the Conversion Shares
issuable upon conversion of the Notes, the issuance of the Warrants and the
reservation for issuance and the issuance of the Warrant Shares upon exercise of
the Warrants, have been duly authorized by the Company's Board of Directors and
no further consent or authorization is required of the Company's Board of
Directors or shareholders (other than the Shareholder Approval, as defined in
Section 4(h) below). The Transaction Documents have been duly executed and
delivered by the Company. The Transaction Documents constitute the valid and
binding obligations of the Company enforceable against the Company in accordance
with their terms, except (i) as rights to indemnification and contribution may
be limited by federal or state securities laws and policies underlying such laws
and (ii) as such enforceability may be limited by general principles of equity
or applicable bankruptcy, insolvency, reorganization, fraudulent conveyance,
moratorium, liquidation or similar laws relating to, or affecting generally, the
enforcement of creditors' rights and remedies.

     (c) Capitalization. Except for any shares issued or issuable pursuant to
employee benefit plans disclosed in the Company's SEC Documents, the
capitalization of the Company is as described in the Company's SEC Documents.
All of the Company's outstanding shares have been, or upon issuance will be,
validly issued and are fully paid and nonassessable and were issued in
accordance with applicable federal and state securities laws. The Company's
Common Stock is registered pursuant to Section 12(g) of the Exchange Act and is
listed for trading on the Principal Market (as defined in Section 4(f) of this
Agreement). Except for rights created pursuant to the Transaction Documents and
as set forth in the SEC Documents, (i) no shares of the Company's capital stock
are subject to preemptive rights or any other similar rights or any liens or
encumbrances created by the Company; (ii) there are no outstanding options,
warrants, scrip, rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into or exchangeable
for, any shares of capital stock of the Company or any of its Subsidiaries, or
contracts, commitments, understandings or arrangements by which the Company or
any of its Subsidiaries is or may become bound to issue additional

                                        9
<PAGE>
shares of capital stock of the Company or any of its Subsidiaries or options,
warrants, scrip, rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into or exchangeable
for, any shares of capital stock of the Company or any of its Subsidiaries
(other than any such options, warrants, scrip, rights, calls, commitments,
securities, understandings and arrangement outstanding under plans disclosed in
the SEC Documents); (iii) there are no outstanding debt securities, notes,
credit agreements, credit facilities or other agreements, documents or
instruments evidencing indebtedness of the Company or any of its Subsidiaries or
by which the Company or any of its Subsidiaries is or may become bound other
than the senior credit facility under that certain Credit Agreement dated July
28, 2004, between the Company and Silicon Valley Bank, as lender, together with
the documents now or hereafter related thereto (including without limitation,
any guarantee agreements and any security documents), in each case as such
agreements may be amended (including any amendment and restatement thereof),
supplemented or otherwise modified from time to time, including any agreement
extending the maturity of, refinancing, replacing, increasing the amount of, or
otherwise restructuring all or any portion of the indebtedness under such
agreement or any successor or replacement agreement and whether by the same or
any other agent, lender or group of lenders (or other institutions) (the "Senior
Facility"); (iv) there are no amounts outstanding under, and there will be no
amounts due upon termination of, any credit agreement or credit facility other
than the Senior Facility; (v) there are no financing statements securing
obligations in any amounts greater than Fifty Thousand United States Dollars
($50,000), singly, or Two Hundred Fifty Thousand United States Dollars
($250,000) in the aggregate, filed in connection with the Company or any of its
Subsidiaries other than in connection with the Senior Facility; (vi) there are
no agreements or arrangements under which the Company or any of its Subsidiaries
is obligated to register the sale of any of its securities under the Securities
Act (other than any such agreements or arrangements disclosed in the SEC
Documents); (vii) there are no outstanding securities or instruments of the
Company or any of its Subsidiaries which contain any redemption or similar
provisions, and there are no contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is or may become
bound to redeem a security of the Company or any of its Subsidiaries; (viii)
there are no securities or instruments containing anti-dilution or similar
provisions that will be triggered by the issuance of the Securities as described
in this Agreement; (ix) the Company does not have any stock appreciation rights
or "phantom" stock plans or agreements or any similar plan or agreement; (x) the
Company and its Subsidiaries have no liabilities or obligations required to be
disclosed in the SEC Documents but not so disclosed in the SEC Documents, other
than those incurred in the ordinary course of the Company's or its Subsidiaries'
respective businesses and which, individually or in the aggregate, do not or
would not have a Material Adverse Effect on the Company and its Subsidiaries
taken as a whole; and (xi) the Company does not have outstanding shareholder
purchase rights or "poison pill" or any similar arrangement in effect giving any
person or entity the right to purchase any equity interest in the Company upon
the occurrence of certain events.

     (d) Issuance of Securities. Except to the extent that the Shareholder
Approval (as defined in Section 4(h) below) is required to authorize sufficient
shares for the conversion of the Notes, the Securities are duly authorized and,
upon issuance in accordance with the terms of the applicable Transaction
Documents, shall be (i) validly issued, fully paid and non-assessable and (ii)
free from all taxes, liens and charges with respect to the issuance thereof,
other than any liens or encumbrances created by or imposed by the Buyers, and
shall not be subject to preemptive

                                       10
<PAGE>
rights or other similar rights of shareholders of the Company. As of the Initial
Closing, 1,783,222 shares of Common Stock will have been duly authorized and
reserved for issuance upon conversion of the Notes and exercise of the Warrants.
Upon conversion or issuance in accordance with the terms of the Notes or upon
exercise or issuance in accordance with the terms of the Warrants, as
applicable, the Conversion Shares and the Warrant Shares, as the case may be,
issued upon such conversion or exercise will be validly issued, fully paid and
non-assessable and free from all preemptive and similar rights, taxes, liens and
charges with respect to the issue thereof, other than any liens or encumbrances
created by or imposed by the Buyers, with the holders being entitled to all
rights accorded to a holder of Common Stock. Subject to the accuracy of the
representations and warranties of each of the Buyers in this Agreement, the
issuance by the Company of the Securities is exempt from registration under the
Securities Act and applicable state securities laws. Once the Shareholder
Approval (as defined in Section 4(h) below) is obtained, the Company shall
reserve sufficient shares for the conversion of the Notes for which sufficient
shares had not been previously reserved by the Company.

     (e) No Conflicts. The execution, delivery and performance of the
Transaction Documents by the Company and the consummation by the Company of the
transactions contemplated hereby and thereby (including, without limitation, the
reservation for issuance and issuance of the Conversion Shares and the Warrant
Shares) will not (i) result in a violation of the Company's Articles of
Incorporation or Bylaws; (ii) conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which the Company or
any of its Subsidiaries is a party, except for such conflicts, defaults,
terminations, amendments, accelerations, cancellations and violations as would
not, individually or in the aggregate, have a Material Adverse Effect; or (iii)
result in a violation of any law, rule, regulation, order, judgment or decree
(including federal and state securities laws and regulations and the rules and
regulations of the Principal Market) applicable to the Company or any of its
Subsidiaries or by which any property or asset of the Company or any of its
Subsidiaries is bound or affected. Neither the Company nor any of its
Subsidiaries is in violation of any material term of or in default under its
Articles of Incorporation, Bylaws or their organizational charter or bylaws,
respectively. Neither the Company nor any of its Subsidiaries is in violation of
any term of or in default under any contract, agreement, mortgage, indebtedness,
indenture, instrument, judgment, decree or order or any statute, rule or
regulation applicable to the Company or its Subsidiaries, except where such
violations and defaults would not result, either individually or in the
aggregate, in a Material Adverse Effect. The business of the Company and its
Subsidiaries is not being conducted in violation of any law, ordinance or
regulation of any governmental entity, except where such violations would not
result, either individually or in the aggregate, in a Material Adverse Effect.
Except as specifically contemplated by this Agreement, as required under the
Securities Act or as required by Blue Sky filings (but only to the extent that
such filings may be made after the Initial Closing), the Company is not required
to obtain any consent, authorization or order of, or make any filing or
registration with, any court or governmental agency or any regulatory or
self-regulatory agency or other person or entity in order for it to execute,
deliver or perform any of its obligations under or contemplated by the
Transaction Documents, except to the extent that the Articles Amendment (as
defined in Section 4(h) below) must be filed with the Secretary of State of the
State of Minnesota. All consents, authorizations, orders, filings and
registrations which the Company is required to obtain pursuant to the preceding
sentence have been obtained or effected

                                       11
<PAGE>
on or prior to the date hereof, and copies of such consents, authorizations,
orders, filings and registrations have been delivered to the Buyers. The Company
is not in violation of the listing requirements of the Principal Market, and has
no actual knowledge of any facts which would reasonably lead to delisting or
suspension of the Common Stock by the Principal Market in the foreseeable
future. The Company and its Subsidiaries are not in violation of any covenants
or other terms of its outstanding indebtedness for borrowed money, which could
reasonably be expected to have a Material Adverse Effect. The Company and its
Subsidiaries are currently unaware of any facts or circumstances which might
give rise to any of the foregoing events set forth in this paragraph.

     (f) SEC Documents; Financial Statements. Since December 31, 2001, the
Company has filed all reports, schedules, forms, statements and other documents
required to be filed by it with the Securities and Exchange Commission (the
"Commission") pursuant to the reporting requirements of the Exchange Act (all of
the foregoing filed prior to or on the date hereof and all exhibits included
therein and financial statements and schedules thereto and documents
incorporated by reference therein being hereinafter referred to as the "SEC
Documents"). As of the date of filing of such SEC Documents, each such SEC
Document complied in all material respects with the requirements of the Exchange
Act applicable to such SEC Document and did not contain any untrue statement of
a material fact or omit to state any material fact necessary in order to make
the statements therein, in light of the circumstances under which they are or
were made, not misleading. As of their respective dates, the financial
statements of the Company included in the SEC Documents complied in all material
respects with applicable accounting requirements and published rules and
regulations of the Commission with respect thereto. Such financial statements
have been prepared in accordance with generally accepted accounting principles,
consistently applied in the United States ("GAAP"), during the periods involved
(except (i) as may be otherwise indicated in such financial statements or the
notes thereto, or (ii) in the case of unaudited interim statements, to the
extent they may exclude footnotes or may be condensed or summary statements),
correspond to the books and records of the Company and fairly present in all
material respects the financial position of the Company and its Subsidiaries as
of the dates thereof and the results of operations and cash flows for the
periods then ended. Ernst & Young LLP is an independent registered public
accounting firm as required by the Exchange Act. The Company is not aware of any
issues raised by the Commission with respect to any of the SEC Documents that
have not been resolved in the ordinary course of review. No other written
information provided by or on behalf of the Company to the Buyers which is not
included in the SEC Documents, including, without limitation, information
referred to in Section 2(d) of this Agreement, contains any untrue statement of
a material fact or omits to state any material fact necessary in order to make
the statements therein, in the light of the circumstances under which they are
or were made, not misleading. The Company satisfies the requirements for use of
Form S-3 for registration of the resale of the Registrable Securities (as that
term is defined in the Registration Rights Agreement) and does not have any
knowledge or reason to believe that it does not satisfy such requirements or
have any knowledge of any fact which would reasonably result in its not
satisfying such requirements. The Company is not required to file and will not
be required to file, any agreement, note, lease, mortgage, deed or other
instrument entered into prior to the date hereof and to which the Company is a
party or by which the Company is bound which has not been previously filed as an
exhibit to its reports filed with the Commission under the Exchange Act, except
for those Transaction Documents required to be filed upon execution and
delivery. Except for the issuance of the Notes and the Warrants contemplated by
this

                                       12
<PAGE>
Agreement, no event, liability, development or circumstance has occurred or
exists, or is currently contemplated to occur, with respect to the Company or
its Subsidiaries or their respective business, properties, prospects, operations
or financial condition, that would be required to be disclosed by the Company
under applicable securities laws and which has not been publicly disclosed. The
Company has no reason to believe that its independent registered public
accounting firm will withhold its consent to the inclusion of its audit opinion
concerning the Company's financial statements which shall be included in the
Registration Statement (as such term is defined in the Registration Rights
Agreement).

     (g) Absence of Litigation. Except as disclosed in the sections titled
"Legal Proceedings" in the SEC Documents, there is no action, suit, proceeding,
inquiry or investigation ("Material Litigation") before or by any court, public
board, government agency, self-regulatory organization or body pending or, to
the knowledge of the Company or any of its Subsidiaries, threatened in writing
against the Company or any of its Subsidiaries or any of the Company's or the
Subsidiaries' officers or directors in their capacities as such that would have
a Material Adverse Effect. The Company believes it has set aside on its books
provisions reasonably adequate for the payment of all judgments, damages, costs,
and expenses arising out of its pending Material Litigation and has
appropriately accounted for such reserves under GAAP.

     (h) No Integrated Offering. Neither the Company, nor any of its affiliates,
nor any person acting on its or their behalf, has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security,
under circumstances that would cause this offering of the Securities to be
integrated with prior offerings by the Company for purposes of the Securities
Act or any applicable shareholder approval provisions, including, without
limitation, under the rules and regulations of any exchange or automated
quotation system on which any of the securities of the Company are listed or
designated, nor will the Company or any of its Subsidiaries take any action or
steps that would cause the offering of the Securities to be integrated with
other offerings.

     (i) Intellectual Property Rights. The Company and its Subsidiaries own,
possess, license or can acquire or make use of on reasonable terms, adequate
rights or licenses to use all trademarks, trade names, trade dress, service
marks, service mark registrations, service names, patents, patent rights,
copyrights, inventions, technology licenses, approvals, governmental
authorizations, trade secrets, and other intellectual property rights
(collectively, "Intellectual Property") necessary to conduct their respective
businesses as now conducted and as currently contemplated to be conducted by
them as described in the SEC Documents, except where the failure to currently
own or possess Intellectual Property would not have a Material Adverse Effect.
The Company and its Subsidiaries do not have any knowledge of any infringement
by the Company or its Subsidiaries of Intellectual Property rights of others, or
of any development of similar or identical trade secrets or technical
information by others that would have a material adverse effect. There is no
claim, action or proceeding being made by the Company or its Subsidiaries
regarding the Intellectual Property rights of the Company or its Subsidiaries or
to the Company's knowledge, brought or currently threatened against the Company
or its Subsidiaries regarding the Intellectual Property rights of or the use of
any Intellectual Property by the Company or its Subsidiaries of any third party
that, if the subject of an unfavorable decision, ruling or finding, would have a
Material Adverse Effect.

                                       13
<PAGE>
     (j) Insurance. The Company and each of its Subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks
and in such amounts as are commensurate with similarly situated companies
engaged in similar businesses as the Company and its Subsidiaries.

     (k) Regulatory Permits. The Company and its Subsidiaries possess all
certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their
respective businesses as currently conducted (the "Permits"), except where the
failure to possess such Permits would not have a Material Adverse Effect, and
neither the Company nor any of its Subsidiaries has received any written notice
of proceedings relating to the revocation or material modification of any such
Permit.

     (l) Tax Status. The Company and each of its Subsidiaries (i) has made or
filed all federal and state income and all other tax returns, reports and
declarations required by any jurisdiction to which it is subject and all such
tax returns are accurate and complete in all material respects, (ii) has paid
all taxes and other governmental assessments and charges due with respect to the
periods covered by such returns, reports and declarations, except those being
contested in good faith and for which the Company has made appropriate reserves
on its books in accordance with GAAP, and (iii) has paid or set aside on its
books provisions reasonably adequate for the payment of all taxes for periods
subsequent to the periods to which such returns, reports or declarations
(referred to in clause (i) above) apply. Except as disclosed in the SEC
Documents, there are no unpaid taxes or assessments for tax deficiencies that
are individually or in the aggregate material in amount claimed to be due by the
taxing authority of any jurisdiction, and the Company knows of no basis for any
such claim, and there are no audits in progress with respect to any tax returns,
no extension of time is in force with respect to any date on which any tax
return was or is to be filed, and no waiver or agreement is in force for the
extension of time for the assessment or payment of any tax. Except as disclosed
in the SEC Documents, all provisions for tax liabilities of the Company and each
of its Subsidiaries have been disclosed in the Company's financial statements
and made in accordance with GAAP consistently applied, and all liabilities for
taxes of the Company and each of its Subsidiaries attributable to periods prior
to or ending on the Closing Date have been adequately disclosed in the Company's
financial statements.

     (m) Application of Takeover Protections. The Company and its Board of
Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or other similar
anti-takeover provision under the Articles of Incorporation, the laws of the
state of its incorporation or the laws of any other state which is applicable to
the Buyers as a result of the transactions contemplated by this Agreement,
including, without limitation, the Company's issuance of the Securities and the
Buyers' ownership, voting or disposition of the Securities.

     (n) Foreign Corrupt Practices. Neither the Company nor any of its
Subsidiaries, nor, to the Company's knowledge, any director, officer, agent,
employee or other person acting on behalf of the Company or any Subsidiary has,
in the course of his actions for, or on behalf of, the Company or any Subsidiary
used any corporate funds for any unlawful contribution, gift, entertainment or
other unlawful expenses relating to political activity; made any direct or
indirect

                                       14
<PAGE>
unlawful payment to any foreign or domestic government official or employee from
corporate funds; violated or is in violation of any provision of the United
States Foreign Corrupt Practices Act of 1977, as amended, or made any bribe,
rebate, payoff, influence payment, kickback or other unlawful payment to any
foreign or domestic government official or employee.

     (o) Confidential Private Placement Memorandum. The information supplied by
the Company for inclusion or incorporation by reference in the Confidential
Private Placement Memorandum dated as of October 6, 2005 (the "Confidential
Private Placement Memorandum") in connection with the offering does not contain
any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they are made, not misleading. If, at any
time prior to the Closing Date, any event with respect to the Company shall
occur which is required to be described in the Confidential Private Placement
Memorandum, such event shall be so described, and an appropriate amendment or
supplement shall be prepared by the Company.

     (p) Transactions With Affiliates. Except as disclosed in the SEC Documents,
other than the grant of stock options granted pursuant to the Company's employee
benefit plans, none of the officers, directors or employees of the Company is
presently a party to any transaction with the Company or any of its Subsidiaries
(other than in connection with the provision of services as employees, officers
and directors), including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of real or
personal property to or from, or otherwise requiring payments to or from any
such officer, director or employee or, to the knowledge of the Company, any
corporation, partnership, trust or other entity in which any such officer,
director, or employee has a substantial interest or is an officer, director,
trustee or partner, such that the transaction would be required to be disclosed
pursuant to Item 404 of Regulation S-K promulgated under the Securities Act.

     (q) Brokers and Finders. Except for fees payable to the Placement Agent as
placement agent, no brokers, finders or financial advisory fees or commissions
will be payable by the Company (or by any Buyer as a result of any actions taken
by the Company) with respect to the transactions contemplated by this Agreement.

     (r) Absence of Certain Changes. Except as disclosed in the SEC Documents
available on the EDGAR system, since December 31, 2004, there has been no change
or development that has had or could reasonably be expected to have, either
individually or in the aggregate, a Material Adverse Effect.

     (s) No Material Non-Public Information. Except for the issuance of the
Securities and the transactions contemplated by this Agreement (which such
information shall be fully disclosed in the Current Report on Form 8-K filed
pursuant to Section 4(g)(1) hereof) and any additional information provided to
any Buyer subject to the terms of a non-disclosure agreement relating
specifically to such information, the Company has not provided the Buyers with,
and the Confidential Private Placement Memorandum does not contain, material
non-public information.

     (t) Acknowledgment Regarding Buyer's Purchase of Securities. The Company
acknowledges and agrees that each Buyer is acting solely in the capacity of
arm's length purchaser with respect to the Transaction Documents and the
transactions contemplated hereby

                                       15
<PAGE>
and thereby and that no Buyer is (i) an officer or director of the Company, (ii)
an "affiliate" of the Company (as defined in Rule 144) or (iii) to the knowledge
of the Company, a "beneficial owner" of more than 10% of the Common Stock (as
defined for purposes of Rule 13d-3 of the Exchange Act). The Company further
acknowledges that no Buyer is acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents
and the transactions contemplated hereby and thereby, and any advice given by a
Buyer or any of its representatives or agents in connection with the Transaction
Documents and the transactions contemplated hereby and thereby is merely
incidental to such Buyer's purchase of the Securities. The Company further
represents to each Buyer that the Company's decision to enter into the
Transaction Documents has been based solely on the independent evaluation by the
Company and its representatives. The Company acknowledges and agrees that no
Buyer makes or has made any representations or warranties with respect to the
transactions contemplated hereby other than those specifically set forth in
Section 2.

     (u) Dilutive Effect. The Company understands and acknowledges that the
number of Conversion Shares issuable upon conversion of the Notes and the
Warrant Shares issuable upon exercise of the Warrants will increase in certain
circumstances. The Company further acknowledges that its obligation to issue
Conversion Shares upon conversion of the Notes in accordance with this
Agreement, the Indenture and the Notes and its obligation to issue the Warrant
Shares upon exercise of the Warrants in accordance with this Agreement, the
Warrant Agent Agreement and the Warrants is, in each case, absolute and
unconditional regardless of the dilutive effect that such issuance may have on
the ownership interests of other shareholders of the Company.

     (v) Insolvency. The Company has not taken any steps to seek protection
pursuant to any bankruptcy law nor does the Company have any knowledge or reason
to believe that its creditors intend to initiate involuntary bankruptcy
proceedings or any actual knowledge of any fact which would reasonably lead a
creditor to do so. The Company is not as of the date hereof, and after giving
effect to the transactions contemplated hereby to occur at the Initial Closing
and the Option Closing, will not be Insolvent (as defined below). For purposes
of this Section 3(v), "Insolvent" means (i) the present fair saleable value of
the Company's assets is less than the amount required to pay the Company's total
debt, (ii) the Company is unable to pay its debts and liabilities, subordinated,
contingent or otherwise, as such debts and liabilities become absolute and
matured, (iii) the Company intends to incur or believes that it will incur debts
that would be beyond its ability to pay as such debts mature or (iv) the Company
has unreasonably small capital with which to conduct the business in which it is
engaged as such business is now conducted and is proposed to be conducted.

     (w) Employee Relations.

     (1) Except as disclosed in the SEC Documents, neither the Company nor any
of its Subsidiaries is a party to any collective bargaining agreement or employs
any member of a union. The Company and its Subsidiaries believe that their
relations with their employees are good. No executive officer of the Company (as
defined in Rule 501(f) of the Securities Act) has notified the Company that such
officer intends to leave the Company or otherwise terminate such officer's
employment with the Company. No executive officer of the Company, to the
knowledge of the Company, is, or is now expected to be, in violation of any
material term of any

                                       16
<PAGE>
employment contract, confidentiality, disclosure or proprietary information
agreement, non-competition agreement, or any other contract or agreement or any
restrictive covenant, and the continued employment of each such executive
officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters.

     (2) The Company and its Subsidiaries are in compliance with all federal,
state, local and foreign laws and regulations respecting employment and
employment practices, terms and conditions of employment and wages and hours,
except where failure to be in compliance would not, either individually or in
the aggregate, reasonably be expected to result in a Material Adverse Effect.

     (x) Title. The Company and its Subsidiaries have good and marketable title
in fee simple to all real property and good and marketable title to all personal
property owned by them which is material to the business of the Company and its
Subsidiaries, in each case free and clear of all liens, encumbrances and defects
except as provided in the SEC Documents or the Senior Facility and except for
such as do not materially affect the value of such property and do not interfere
with the use made and proposed to be made of such property by the Company and
any of its Subsidiaries. Any real property and facilities held under lease by
the Company and any of its Subsidiaries are held by them under valid, subsisting
and enforceable leases with such exceptions as are not material and do not
interfere with the use made and proposed to be made of such property and
facilities by the Company and its Subsidiaries.

     (y) Environmental Laws. The Company and its Subsidiaries (i) are in
compliance with any and all Environmental Laws (as hereinafter defined), (ii)
have received all permits, licenses or other approvals required of them under
applicable Environmental Laws to conduct their respective businesses and (iii)
are in compliance with all terms and conditions of any such permit, license or
approval where, in each of the foregoing clauses (i), (ii) and (iii), the
failure to so comply could be reasonably expected to have, individually or in
the aggregate, a Material Adverse Effect. The term "Environmental Laws" means
all federal, state, local or foreign laws relating to pollution or protection of
human health or the environment (including, without limitation, ambient air,
surface water, groundwater, land surface or subsurface strata), including,
without limitation, laws relating to emissions, discharges, releases or
threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, "Hazardous Materials") into the
environment, or otherwise relating to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands or demand letters,
injunctions, judgments, licenses, notices or notice letters, orders, permits,
plans or regulations issued, entered, promulgated or approved thereunder.

     (z) Subsidiary Rights. The Company or one of its Subsidiaries has the
unrestricted right to vote, and (subject to limitations imposed by applicable
law) to receive dividends and distributions on, all capital securities of its
Subsidiaries as owned by the Company or such Subsidiary.

     (aa) Internal Accounting Controls. The Company and each of its Subsidiaries
maintain a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with
management's general or specific authorizations,

                                       17
<PAGE>
(ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset and liability
accountability, (iii) access to assets or incurrence of liabilities is permitted
only in accordance with management's general or specific authorization and (iv)
the recorded accountability for assets and liabilities is compared with the
existing assets and liabilities at reasonable intervals and appropriate action
is taken with respect to any difference.

     (bb) Sarbanes-Oxley Act. The Company is in compliance with any and all
applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective
with respect to the Company as of the date hereof, and any and all applicable
rules and regulations promulgated by the SEC thereunder that are effective with
respect to the Company as of the date hereof, except where such noncompliance
would not have, individually or in the aggregate, a Material Adverse Effect.

     SECTION 4. COVENANTS.

     (a) Obligations. Each party shall use commercially reasonable efforts to
timely satisfy each of the conditions to be satisfied by it as provided in
Sections 6 and 7 of this Agreement.

     (b) Form D and Blue Sky. The Company agrees to file timely a Form D with
the Commission with respect to the Securities as required under Regulation D and
to provide, upon request, a copy thereof to each Buyer. The Company shall, on or
before the Closing Date and on or before the Option Closing Date, take such
action as the Company shall reasonably determine is necessary in order to obtain
an exemption for, or to qualify the Securities for, sale to the Buyers at the
Initial Closing and the Option Closing pursuant to this Agreement under
applicable securities or "Blue Sky" laws of the states of the United States (or
to obtain an exemption from such qualification), in those jurisdictions
identified by the Buyers and shall provide evidence of any such action so taken
to the Buyers on or prior to the Closing Date and the Option Closing Date. The
Company shall make all timely filings and reports relating to the offer and sale
of the Securities required under applicable securities or "Blue Sky" laws of the
states of the United States following the Closing Date and the Option Closing
Date. The Company shall pay all fees and expenses in connection with satisfying
its obligations under this Section 4(b).

     (c) Reporting Status. With a view to making available to the Investors (as
that term is defined in the Registration Rights Agreement) the benefits of Rule
144 promulgated under the Securities Act or any similar rule or regulation of
the Commission that may at any time permit the Investors to sell securities of
the Company to the public without registration ("Rule 144"), the Company shall:
(i) make and keep public information available, as those terms are understood
and defined in Rule 144; (ii) file with the Commission in a timely manner all
reports and other documents required of the Company under the Securities Act and
the Exchange Act; and (iii) furnish to each Investor, so long as such Investor
owns Registrable Securities (the "Reporting Period"), promptly upon request, (A)
a written statement by the Company, if true, that it has complied with the
applicable reporting requirements of Rule 144, the Securities Act and the
Exchange Act, (B) a copy of the most recent annual or quarterly report of the
Company and copies of such other reports and documents so filed by the Company,
(C) the information required by Rule 144A(d)(4) (or any successor rule) under
the Securities Act, and (D) such other

                                       18
<PAGE>
information as may be reasonably requested to permit the Investors to sell such
securities pursuant to Rule 144 without registration.

     (d) Use of Proceeds. The Company intends to use the net proceeds from the
sale of the Notes and the Warrants as described in the Confidential Private
Placement Memorandum.

     (e) Reservation of Shares. The Company shall provide, free from preemptive
rights, out of its authorized but unissued shares, reserved for the purpose of
issuance, no less than one hundred five percent (105%) of the number of shares
of Common Stock needed to provide for the issuance of the Conversion Shares upon
conversion of all of the Notes and the Warrant Shares upon exercise of all of
the Warrants without regard to any limitations on conversions or exercise;
provided that until such date, if any, after the date hereof, as the
shareholders of the Company approve an increase in the authorized capital stock
of the Company such that there are sufficient shares therefor (the "Approval
Date"), the number of shares required to be reserved for conversion of the Notes
shall be reduced to the total number of the Company's authorized but unissued
shares that, as of the date hereof, are available for issuance and have not been
reserved by the Company's Board of Directors for a specific purpose as of the
date hereof including issuance under any existing stock option or other equity
plan of the Company or other obligation of the Company to issue shares of Common
Stock (including the Warrants).

     (f) Listing. The Company shall promptly use its best efforts to secure the
listing of all of the Conversion Shares and the Warrant Shares upon each
national securities exchange and automated quotation system, if any, upon which
shares of Common Stock are then listed (subject to official notice of issuance)
and, shall maintain, so long as any other shares of Common Stock shall be so
listed, such listing of all Conversion Shares and Warrant Shares from time to
time issuable under the terms of the Transaction Documents. So long as any
Securities are outstanding, the Company shall maintain the Common Stock's
authorization for quotation or listing on The New York Stock Exchange, Inc. (the
"NYSE"), the American Stock Exchange, Inc. ("AMEX") or The Nasdaq National
Market or SmallCap Market ("NASDAQ") (as applicable, the "Principal Market").
The Company shall pay all fees and expenses in connection with satisfying its
obligations under this Section 4(f).

     (g) Filing of Form 8-K. On or before 8:30 a.m., New York Time, on the
Business Day following the Closing Date, the Company shall issue a press release
announcing the transactions contemplated hereby. The Company shall use
reasonable efforts within one Business Day (as defined below) after the public
announcement of the transactions contemplated hereby to file (i) a Current
Report on Form 8-K with the Commission furnishing as an exhibit to such Current
Report on Form 8-K the press release announcing the signing of this Agreement
after the issuance of such press release, and (ii) a Current Report on Form 8-K
(which may be the same Form 8-K described in clause (i) above) with the
Commission describing the terms of the transactions contemplated by the
Transaction Documents and including as exhibits to such Current Report on Form
8-K (A) this Agreement and the Exhibits hereto, (B) the form of Note, (C) the
form of Warrant, (D) the Registration Rights Agreement, (E) the form of
Indenture, and (F) the form of Warrant Agent Agreement, each in the form
required by the Exchange Act; provided, however, that no references to the names
of the Buyers shall be included in any press release filed in connection with
the transactions contemplated hereby. "Business Day" means

                                       19
<PAGE>
any day other than Saturday, Sunday or other day on which commercial banks in
the City of New York are required by law to remain closed.

     (h) Shareholder Approval. In the event that Shareholder Approval (as
defined below) is required (i) pursuant to the rules of the Principal Market for
the issuance of a number of Conversion Shares or Warrant Shares greater in the
aggregate than 19.99% of the number of shares of Common Stock outstanding
immediately prior to the Closing Date (the "19.99% Rule"), or (ii) to amend the
Company's Articles of Incorporation (the "Articles Amendment") to increase the
number of authorized shares so that they are sufficient to allow for the
reservation and issuance of one hundred five percent (105%) of the Conversion
Shares, then, in the case of the 19.99% Rule, the Company shall provide each
shareholder entitled to vote at the next meeting of shareholders of the Company
(which meeting shall occur on or before ninety (90) days from the date of such
determination), a proxy statement, and, in the case of the Articles Amendment,
the Company shall provide each shareholder entitled to vote at the next annual
meeting of shareholders of the Company (which meeting shall occur on or before
June 30, 2006) (the "2006 Annual Meeting") a proxy statement, each soliciting
each such shareholder's affirmative vote at such shareholder meeting for
approval of such issuance or such amendment (such affirmative approval being
referred to herein as the "Shareholder Approval"), and the Company shall use its
best efforts to obtain such Shareholder Approval. Such proxy statements shall
have been previously reviewed by the Placement Agent, the Buyers and a counsel
of their choice. If the Articles Amendment is not approved by the Company's
shareholders at the 2006 Annual Meeting, the Company shall use its best efforts
to obtain Shareholder Approval of the Articles Amendment at the Company's annual
meeting of shareholders in 2007 (which meeting shall occur on or before June 30,
2007).

     (i) Expenses. Subject to Section 9(n) of this Agreement, at the Initial
Closing, the Company shall reimburse the Buyers for the fees and expenses of
Buyers' counsel incurred in connection with the consummation of the transactions
contemplated by this Agreement, up to a maximum of $40,000, which amount shall
be paid by the Company to the Buyers concurrently with the Company's receipt of
the purchase price at the Initial Closing and shall be allocated pro rata among
the Buyers based on the respective principal amount of Initial Notes set forth
opposite such Buyer's name on the Schedule of Buyers attached hereto as Exhibit
A.

     (j) Additional Securities. For so long as any Buyer beneficially owns any
Securities, the Company will not issue any Notes or Warrants other than to the
Buyers as contemplated hereby and the Company shall not issue any other
securities that would cause a breach or default under the Notes.

     (k) Tax Matters. If the Company shall be required to withhold or deduct any
tax or other governmental charge from any payment made hereunder or under any
Note to any Buyer, then, subject to the last sentence of this Section 4(k), the
Company shall pay to such Buyer such additional amounts as are necessary such
that such Buyer actually receives the amount such Buyer would have received if
no such withholding or deduction had been required. If any Buyer is organized
under the laws of a jurisdiction other than the United States, any State thereof
or the District of Columbia (a "Non-United States Buyer"), such Buyer shall
deliver to the Company either (i) two (2) copies of either United States
Internal Revenue Service Form W-8BEN or Form W-8ECI, or (ii) in the case of a
Non-United States Buyer claiming exemption from United States

                                       20
<PAGE>
Federal withholding tax under Section 871(h) or 881(c) of the Internal Revenue
Code of 1986, as amended, and the rules and regulations promulgated thereunder
(the "Code") with respect to payments of "portfolio interest", a certificate in
form and substance reasonably acceptable to the Company representing that such
Non-United States Buyer is not a bank for purposes of Section 881(c) of the
Code, is not a ten percent (10%) shareholder (within the meaning of Section
871(h)(3)(B) of the Code) of the Company and is not a controlled foreign
corporation related to the Company (within the meaning of Section 864(d)(4) of
the Code), together with Internal Revenue Service Form W-8 or W-9, as
applicable, in all cases such forms and other documents being properly completed
and duly executed by such Non-United States Buyer claiming complete exemption
from United States Federal withholding tax on payments of interest by the
Company (or accruals of original issue discount) under the Notes. In addition,
each Buyer that is not otherwise exempt from "back-up withholding" shall deliver
to the Company properly completed and duly executed Internal Revenue Service
Form W-8 or W-9 indicating that such Buyer is subject to "back-up withholding"
for United States Federal income tax purposes. The forms and other documents
required to be delivered pursuant to the two preceding sentences shall be
delivered within ten (10) days after the Closing Date and, if requested by the
Company, any Option Closing Date. The Company shall not be required to pay any
additional amounts (x) to any Non-United States Buyer in respect of United
States Federal withholding tax or (y) to any Buyer in respect of United States
Federal "back-up withholding" tax to the extent that the obligation to pay such
additional amounts would not have arisen but for a failure by such Non-United
States Buyer or Buyer, as the case may be, to comply with the provisions of this
Section 4(k).

     (l) Violation of Laws. The business of the Company and its Subsidiaries
shall not be conducted in violation of any law, ordinance or regulation of any
governmental entity, except where such violations would not result, either
individually or in the aggregate, in a Material Adverse Effect.

     (m) Limits on Additional Issuances. The Company shall not, in any manner,
until the later of (i) 180 days after the Initial Closing or (ii) the date on
which the Registration Statement required to be filed pursuant to Section 2(a)
of the Registration Rights Agreement is declared effective by the Commission,
issue or sell any Common Stock or rights, warrants or options to subscribe for
or purchase Common Stock or any security directly or indirectly convertible into
or exchangeable or exercisable for Common Stock (the "Equity Limitation"). The
Equity Limitation shall not apply (i) to the issuance of the Additional Notes
and the Additional Warrants, (ii) to the issuance of Conversion Shares or
Warrant Shares, as the case may be, pursuant to the Notes or the Warrants, (iii)
to the issuance of securities pursuant to the conversion or exchange of
convertible or exchangeable securities or the exercise of warrants or options,
in each case outstanding on the date hereof, provided such securities, warrants
and options are not amended after the date hereof, (iv) if holders representing
a majority of the outstanding principal amount of the Notes give their prior
written consent to such issuance or sale, (v) if the issuance is pursuant to
employee benefits plans approved by the Company's Board of Directors, (vi) to
the filing of a Registration Statement on Form S-8, (vii) if the securities are
issued for consideration other than cash in connection with a bona fide business
acquisition by the Company whether by merger, consolidation, purchase of assets,
sale or exchange of stock or otherwise, or (viii) if the issuance is in
connection with a (A) commercial banking arrangement, (B) equipment financing,
(C) sponsored research, (D) collaboration, (E) technology licensing,

                                       21
<PAGE>
(F) development agreement or (G) other strategic partnership; provided, however,
that with respect to (C) through (G) hereof, the primary purpose of such
transaction is not to raise equity capital.

     (n) CUSIP Numbers. The Company in issuing the Securities shall use "CUSIP"
numbers (if then generally in use), and shall use such "CUSIP" numbers in
notices to holders as a convenience to holders thereof; provided that any such
notice may state that no representation is made as to the correctness of such
numbers either as printed on the Securities or as contained in any notice to
such holders and that reliance may be placed only on other identification
numbers printed on such Securities, and any such Company action referenced in
such notice (including, without limitation, redemption or automatic conversion
of Notes) shall not be affected by any defect in or omission of such numbers.

     (o) [Reserved].

     (p) Nonpublic Information. The Company shall not, and shall cause each of
its Subsidiaries and its and each of their respective officers, directors,
employees and agents, not to, provide those Buyers listed on Schedule 4(p) with
any material, nonpublic information regarding the Company or any of its
Subsidiaries from and after the filing of the Form 8-K(s) with the SEC pursuant
to Section 4(g) hereof without the express written consent of such Buyers;
provided, however, that the foregoing shall not restrict in any way the
distribution of any information to any such Buyers by the Company or its
Subsidiaries and its and each of their respective officers, directors, employees
and agents (i) as reasonably required by the terms of the Transaction Documents
or (ii) in connection with any request by or on behalf of the Company to waive,
amend or modify any provision of the Transaction Documents.

     (q) PORTAL Market. The Company will use its best efforts to permit the
Notes to be designated securities eligible for trading in The Portal Market in
accordance with the rules and regulations adopted by the NASD relating to
trading in The Portal Market and to permit the Notes to be eligible for
clearance and settlement through the Depository Trust Company.

     (r) Independent Nature of Buyers' Obligations and Rights. The obligations
of each Buyer under any Transaction Document are several and not joint with the
obligations of any other Buyer, and no Buyer shall be responsible in any way for
the performance of the obligations of any other Buyer under any Transaction
Document. Nothing contained herein or in any other Transaction Document, and no
action taken by any Buyer pursuant hereto or thereto, shall be deemed to
constitute the Buyers as a partnership, an association, a joint venture or any
other kind of entity, or create a presumption that the Buyers are in any way
acting in concert or as a group with respect to such obligations or the
transactions contemplated by the Transaction Documents. Each Buyer confirms that
it has independently participated in the negotiation of the transaction
contemplated hereby with the advice of its own counsel and advisors. Except as
provided by the Transaction Documents, each Buyer shall be entitled to
independently protect and enforce its rights, including, without limitations,
the rights arising out of this Agreement or out of any other Transaction
Documents, and it shall not be necessary for any other Buyer to be joined as an
additional party in any proceeding for such purpose.

                                       22
<PAGE>
     SECTION 5. TRANSFER AGENT INSTRUCTIONS. The Company shall issue irrevocable
instructions to its transfer agent, and any subsequent transfer agent, to issue
certificates or credit shares to the applicable balance accounts at The
Depository Trust Company ("DTC"), registered in the name of each Buyer or their
respective nominee(s), for the Conversion Shares and Warrant Shares in such
amounts as specified from time to time by a Buyer to the Company upon conversion
of the Notes or exercise of the Warrants, as applicable and in accordance with
their respective terms (the "Irrevocable Transfer Agent Instructions"),
substantially in the form attached hereto as Exhibit F. Prior to transfer or
sale pursuant to a registration statement or Rule 144 under the Securities Act
of the Conversion Shares and the Warrant Shares, all such certificates shall
bear the restrictive legend specified in Section 2(g) of this Agreement except
as otherwise provided herein. The Company represents and warrants that no
instruction inconsistent with the Irrevocable Transfer Agent Instructions
referred to in this Section 5 will be given by the Company to its transfer agent
and that the Securities shall be freely transferable on the books and records of
the Company as and to the extent provided in this Agreement, the Notes, the
Indenture, the Warrants, the Warrant Agent Agreement and the Registration Rights
Agreement. Subject to the Indenture and the Warrant Agent Agreement, if a Buyer
provides the Company with an opinion of counsel, in form reasonably acceptable
to the Company, to the effect that a public sale, assignment or transfer of the
Securities has been made without registration under the Securities Act or that
the Securities can be sold pursuant to Rule 144(k) without any restriction as to
the number of securities acquired as of a particular date that can then be
immediately sold, and provides such representations that the Company shall
reasonably request confirming compliance with the requirements of Rule 144, the
Company shall permit the transfer, and, in the case of the Conversion Shares and
the Warrant Shares, promptly instruct its transfer agent to issue one or more
certificates, or credit shares to one or more balance accounts at DTC, in such
name and in such denominations as specified by such Buyer and without any
restrictive legend. The Company acknowledges that a breach by it of its
obligations hereunder will cause irreparable harm to the Buyers by vitiating the
intent and purpose of the transaction contemplated hereby. Accordingly, the
Company acknowledges that the remedy at law for a breach of its obligations
under this Section 5 will be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Section 5, that the
Buyers shall be entitled, in addition to all other available remedies, to an
order and/or injunction restraining any breach and requiring immediate issuance
and transfer, without the necessity of showing economic loss and without any
bond or other security being required.

     SECTION 6. CONDITIONS TO THE COMPANY'S OBLIGATION TO CLOSE. The obligation
of the Company to issue and sell the Notes and the Warrants to each respective
Buyer at the Initial Closing or the Option Closing, as the case may be, is
subject to the satisfaction, at or before the Closing Date or the Option Closing
Date, as the case may be, of each of the following conditions, provided that
these conditions are for the Company's sole benefit and may be waived by the
Company at any time in its sole discretion by providing such Buyer with prior
written notice thereof:

     (a) Transaction Documents. Such Buyer shall have executed each of the
Transaction Documents to which it is a party and delivered the same to the
Company.

     (b) Payment of Purchase Price. Such Buyer shall have delivered to the
Company the purchase price for the Notes and the Warrants being purchased by
such Buyer at the Initial

                                       23
<PAGE>
Closing or the Option Closing, as the case may be, by wire transfer of
immediately available funds pursuant to the wire instructions attached hereto as
Schedule A.

     (c) Representations and Warranties; Covenants. The representations and
warranties of such Buyer shall be true, correct and complete in all material
respects (except to the extent that any of such representations and warranties
is already qualified as to materiality in Section 2 above, in which case such
representations and warranties shall be true, correct and complete without
further qualification) as of the date when made, and as of the Closing Date or
the Option Closing Date, as the case may be, as though made at that time (except
for representations and warranties that speak as of a specific date (which shall
be true, correct and complete as of such date)), and such Buyer shall have
performed, satisfied and complied with in all material respects the covenants,
agreements and conditions required by the Transaction Documents to be performed,
satisfied or complied with by such Buyer at or prior to the Closing Date or the
Option Closing Date, as the case may be.

     SECTION 7. CONDITIONS TO EACH BUYER'S OBLIGATION TO PURCHASE. The several
obligations of each Buyer hereunder to purchase the Notes and the Warrants from
the Company at the Initial Closing or the Option Closing, as the case may be, is
subject to the satisfaction, at or before the Closing Date or the Option Closing
Date, as the case may be, of each of the following conditions, provided that
these conditions are for each Buyer's sole benefit and may be waived by such
Buyer at any time in its sole discretion by providing the Company with prior
written notice thereof:

     (a) Transaction Documents. The Company shall have executed each of the
Transaction Documents and delivered the same to such Buyer. The Trustee shall
have executed and delivered the Indenture to the Company. The Warrant Agent
shall have executed and delivered the Warrant Agent Agreement to the Company.

     (b) No Delisting of Common Stock. The Common Stock (i) shall be designated
for quotation or listed on the Principal Market and (ii) shall not have been
suspended by the Commission or the Principal Market from trading on the
Principal Market nor shall suspension by the Commission or the Principal Market
have been threatened either (A) in writing by the Commission or the Principal
Market or (B) by falling below the minimum listing maintenance requirements of
the Principal Market.

     (c) Representations and Warranties; Covenants. The representations and
warranties of the Company shall be true, correct and complete in all material
respects (except to the extent that any of such representations and warranties
is already qualified as to materiality in Section 3 of this Agreement, in which
case such representations and warranties shall be true, correct and complete
without further qualification) as of the date when made, and as of the Closing
Date or the Option Closing Date, as the case may be, as though made at that time
(except for representations and warranties that speak as of a specific date
(which shall be true, correct and complete as of such date)) and the Company
shall have performed, satisfied and complied with in all material respects the
covenants, agreements and conditions required by the Transaction Documents to be
performed, satisfied or complied with by the Company at or prior to the Closing
Date or the Option Closing Date, as the case may be. Such Buyer shall have
received a certificate, executed by the Chief Executive Officer or Chief
Financial Officer of the Company,

                                       24
<PAGE>
dated as of the Closing Date or the Option Closing Date, as the case may be, to
the foregoing effect.

     (d) Opinion of Counsel. The Company shall have delivered to such Buyer the
opinion of Dorsey & Whitney LLP, dated as of the Closing Date or the Option
Closing Date, as the case may be, in the form of Exhibit G attached hereto.

     (e) Delivery of Notes and Warrants. The Company shall have executed and
delivered to such Buyer the Notes and the Warrants (in such denominations of not
less than One Thousand United States Dollars ($1,000) as such Buyer shall
reasonably request) for the Notes and the Warrants being purchased by such Buyer
at the Initial Closing or the Option Closing, as the case may be.

     (f) Reservation of Common Stock. As of the Closing Date or the Option
Closing Date, as the case may be, the Company shall have reserved out of its
authorized and unissued Common Stock, solely for the purpose of effecting the
conversion of the Notes and the exercise of the Warrants, the number of shares
of Common Stock necessary for the conversion of the Notes and the exercise of
the Warrants, except to the extent that the Shareholder Approval may be required
to reserve all of the Conversion Shares.

     (g) Irrevocable Transfer Agent Instructions. The Company shall have
delivered the Irrevocable Transfer Agent Instructions, in the form of Exhibit F
attached hereto, to the Company's transfer agent.

     (h) Good Standing Certificate. The Company shall have delivered to the
Placement Agent (i) a certificate evidencing the incorporation and good standing
of the Company in Minnesota issued by the Secretary of State of the State of
Minnesota as of a recent date; and (ii) a certificate of good standing (or
appropriate counterpart) from the appropriate governmental authority in each
domestic jurisdiction in which Significant Subsidiaries are incorporated or
organized as of a recent date.

     (i) Secretary's Certificate. The Company shall have delivered to such Buyer
a secretary's certificate, dated as of the Closing Date or the Option Closing
Date, as the case may be, certifying as to (i) adoption of the form of
resolutions of the Board of Directors of the Company consistent with Section
3(b) of this Agreement and in a form reasonably acceptable to such Buyer, (ii)
the Articles of Incorporation and (iii) the Bylaws, each as in effect at the
Initial Closing or the Option Closing, as the case may be.

     (j) Filings; Authorizations. The Company shall have made all filings under
all applicable federal and state securities laws necessary to consummate the
issuance of the Securities pursuant to this Agreement in compliance with such
laws, and shall have obtained all authorizations, approvals and permits
necessary to consummate the transactions contemplated by the Transaction
Documents and such authorizations, approvals and permits shall be effective as
of the Closing Date or the Option Closing Date, as the case may be.

     (k) No Injunctions. No temporary restraining order, preliminary or
permanent injunction or other order or decree, and no other legal restraint or
prohibition shall exist which

                                       25
<PAGE>
prevents or arguably prevents the consummation of the transactions contemplated
by the Transaction Documents, nor shall any proceeding have been commenced or
threatened with respect to the foregoing.

     (l) No Material Adverse Effect. Between the time of execution of this
Agreement and the Closing Date, or between the time of execution of this
Agreement and the Option Closing Date, as the case may be, (i) no Material
Adverse Effect shall occur or become known (whether or not arising in the
ordinary course of business) and (ii) no transaction which is material and
unfavorable to the Company shall have been entered into by the Company.

     (m) Payment of Fees. The Company shall have satisfied its obligations under
Section 9(o) of this Agreement.

     (n) Minimum Offering. The Company shall have confirmed in writing to the
Buyers that it will be issuing at least an aggregate of $19,000,000 principal
amount of Notes and Warrants to the Buyers on the Closing Date.

     (o) No Stop Orders. No stop order or suspension of trading shall have been
imposed by the Principal Trading Market, the Commission or any other
governmental or regulatory body with respect to public trading in the Common
Stock.

     SECTION 8. INDEMNIFICATION.

     (a) Indemnification by the Company. In consideration of each Buyer's
execution and delivery of the Transaction Documents and acquiring the Securities
thereunder and the Placement Agent's agreement to act as exclusive placement
agent and in addition to all of the Company's other obligations under the
Transaction Documents, the Company shall defend, protect, indemnify and hold
harmless the Placement Agent and each Buyer and each other holder of the
Securities and all of their shareholders, partners, members, officers,
directors, employees and direct or indirect investors and any of the foregoing
persons' agents or other representatives (including, without limitation, those
retained in connection with the transactions contemplated by this Agreement)
(collectively, the "Indemnitees") from and against any and all actions, causes
of action, suits, claims, losses, costs, penalties, fees, liabilities and
damages, and expenses in connection therewith (irrespective of whether any such
Indemnitee is a party to the action for which indemnification hereunder is
sought), and including reasonable attorneys' fees and disbursements
(collectively, "Claims"), incurred by any Indemnitee as a result of, or arising
out of, or relating to (i) an untrue statement or alleged untrue statement of a
material fact contained in the Confidential Private Placement Memorandum, or in
any amendment or supplement thereto, or in any Blue Sky filings executed by the
Company or based on any information furnished in writing by the Company and
filed in any jurisdiction in order to qualify any or all of the Securities under
(or obtain exemption from) the securities laws thereof, or arise out of or are
based upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading, or (ii)
any breach of any representation, warranty, covenant or agreement made by the
Company in the Transaction Documents or other certificate, instrument or
document contemplated hereby or thereby. To the extent that the foregoing
undertaking by the Company may be unenforceable for any reason, the Company
shall make the maximum

                                       26
<PAGE>
contribution to the payment and satisfaction of each of the Claims which is
permissible under applicable law. Subject to Section 8(b) of this Agreement, the
Company shall reimburse the Indemnitees, promptly as such expenses are incurred
and are due and payable, for any legal fees or other reasonable expenses
incurred by them in connection with the investigating or defending any such
Claim.

     (b) Procedures for Indemnification. Promptly after an Indemnitee has
knowledge of any Claim as to which such Indemnitee reasonably believes indemnity
may be sought or promptly after such Indemnitee receives notice of the
commencement of any action or proceeding (including any governmental action or
proceeding) involving a Claim, such Indemnitee shall, if a Claim in respect
thereof is to be made against the Company under this Section 8, deliver to the
Company a written notice of such Claim, and the Company shall have the right to
participate in, and, to the extent the Company so desires, to assume control of
the defense thereof with counsel mutually satisfactory to the Company and the
Indemnitee; provided, however, that an Indemnitee shall have the right to retain
its own counsel if, in the reasonable opinion of counsel retained by the
Company, the representation by such counsel of the Indemnitee and the Company
would be inappropriate due to actual or potential differing interests between
such Indemnitee and the Company; provided, further, that the Company shall not
be responsible for the reasonable fees and expense of more than one (1) separate
legal counsel for such Indemnitee. In the case of an Indemnitee, the legal
counsel referred to in the immediately preceding sentence shall be selected by
the Investors holding at least a majority in interest of the Securities to which
the Claim relates. The Indemnitee shall cooperate fully with the Company in
connection with any negotiation or defense of any such action or Claim by the
Company and shall furnish to the Company all information reasonably available to
the Indemnitee which relates to such action or Claim. The Company shall keep the
Indemnitee fully apprised at all times as to the status of the defense or any
settlement negotiations with respect thereto. The Company shall not be liable
for any settlement of any Claim effected without its prior written consent;
provided, however, that the Company shall not unreasonably withhold, delay or
condition its consent. The Company shall not, without the prior written consent
of the Indemnitee, consent to entry of any judgment or enter into any settlement
or other compromise which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such Indemnitee of a full release from
all liability in respect to such Claim, action and proceeding. The failure to
deliver written notice to the Company as provided in this Agreement shall not
relieve the Company of any liability to the Indemnitee under this Section 8,
except to the extent that the Company is materially prejudiced in its ability to
defend such action.

     (c) Survival of Representations and Warranties; Indemnification
Obligations. The representations and warranties of the Buyers and the Company
set forth herein and the obligations of the Company under this Section 8 shall
survive the transfer of the Securities by the Indemnitees.

     SECTION 9. MISCELLANEOUS.

     (a) Governing Law; Jurisdiction; Waiver of Jury Trial. All questions
concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by the internal laws of the State of New York,
without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would

                                       27
<PAGE>
cause the application of the laws of any jurisdictions other than the State of
New York. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by
mailing a copy thereof to such party at the address for such notices to it under
this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.
If any provision of this Agreement shall be invalid or unenforceable in any
jurisdiction, such invalidity or unenforceability shall not affect the validity
or enforceability of the remainder of this Agreement in that jurisdiction or the
validity or enforceability of any provision of this Agreement in any other
jurisdiction. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY
JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT
COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

     (b) Counterparts. This Agreement may be executed in identical counterparts,
each of which shall be deemed an original but all of which shall constitute one
and the same agreement. This Agreement, once executed by a party, may be
delivered to the other parties hereto by facsimile transmission of a copy of
this Agreement bearing the signature of the party so delivering this Agreement.

     (c) Headings. The headings of this Agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof.

     (d) Entire Agreement. This Agreement, the Registration Rights Agreement,
the Indenture, the Warrant Agent Agreement, the Notes and the Warrants and the
documents referenced herein and therein constitute the entire agreement among
the parties hereto with respect to the subject matter hereof and thereof. There
are no restrictions, promises, warranties or undertakings, other than those set
forth or referred to herein and therein. This Agreement, the Registration Rights
Agreement, the Indenture, the Warrant Agent Agreement, the Notes and the
Warrants supersede all prior agreements and understandings among the parties
hereto with respect to the subject matter hereof and thereof.

     (e) Consents. All consents and other determinations required to be made by
Buyers pursuant to this Agreement shall be made, unless otherwise specified in
this Agreement, by Buyers holding at least a majority of the Conversion Shares
and the Warrant Shares, determined as if all of the Notes held by Buyers then
outstanding have been converted into Conversion Shares and all Warrants then
outstanding have been exercised for Warrant Shares without regard to any
limitations on conversion of the Notes or on the exercise of the Warrants.

     (f) Waivers. No provision of this Agreement may be amended or waived other
than by an instrument in writing signed by the Company and Buyers holding at
least a majority of the Conversion Shares and the Warrant Shares, determined as
if all of the Notes held by Buyers then outstanding have been converted into
Conversion Shares and all Warrants then outstanding have been exercised for
Warrant Shares without regard to any limitations on the conversion of the Notes
or on the exercise of the Warrants. No such amendment shall be effective to the
extent that it applies to less than all of the holders of the Notes then
outstanding. No consideration shall be offered or paid to any holder of any
Securities to amend or consent to a waiver or

                                       28
<PAGE>
modification of any provision of any of the Transaction Documents unless the
same consideration is offered to all of the holders of such Securities.

     (g) Notices. Any notices, consents, waivers or other communications
required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered: (i) upon receipt, when
delivered personally; (ii) upon receipt, when sent by facsimile; or (iii) one
(1) Business Day after deposit with a nationally recognized overnight delivery
service, in each case properly addressed to the party to receive the same. The
addresses and facsimile numbers for such communications shall be:

     If to the Company:

          ATS Medical, Inc.
          3905 Annapolis Lane, Suite 105
          Minneapolis, Minnesota 55447
          Telephone: (763) 553-7736
          Facsimile: (763) 557-2244
          Attention: Mr. John R. Judd

     with a copy to:

          Dorsey & Whitney LLP
          50 South Sixth Street, Suite 1500
          Minneapolis, Minnesota 55402
          Telephone: (612) 340-2600
          Facsimile: (612) 340-2868
          Attention: Timothy S. Hearn, Esq.

     If to the Placement Agent:

          Piper Jaffray & Co.
          345 California Street, Suite 2100
          San Francisco, California 94104
          Telephone: (415) 984-5126
          Facsimile: (415) 984-5121
          Attention: Mr. Eric Alt

     with a copy to:

          Latham & Watkins LLP
          650 Town Center Drive, 20th Floor
          Costa Mesa, California 92626
          Telephone: (714) 540-1235
          Facsimile: (714) 755-8290
          Attention: R. Scott Shean, Esq.

                                       29
<PAGE>
     If to a Buyer, to its address and facsimile number set forth on the
     Schedule of Buyers attached hereto as Exhibit A, with copies to such
     Buyer's representatives as set forth on the Schedule of Buyers,

or at such other address and/or facsimile number and/or to the attention of such
other person as the recipient party has specified by written notice given to
each other party. Written confirmation of receipt (A) given by the recipient of
such notice, consent, waiver or other communication, (B) mechanically or
electronically generated by the sender's facsimile machine containing the time,
date, recipient facsimile number and an image of the first page of such
transmission or (C) provided by a nationally recognized overnight delivery
service shall be rebuttable evidence of personal service, receipt by facsimile
or receipt from a nationally recognized overnight delivery service in accordance
with clause (i), (ii) or (iii) above, respectively.

     (h) Further Assurances. Each party shall do and perform, or cause to be
done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

     (i) Third-Party Beneficiaries. This Agreement is intended for the benefit
of the parties hereto and their respective permitted successors and assigns, and
is not for the benefit of, nor may any provision hereof be enforced by, any
other person other than the Placement Agent.

     (j) Severability. If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or unenforceability shall not
affect the validity or enforceability of the remainder of this Agreement in that
jurisdiction or the validity or enforceability of any provision of this
Agreement in any other jurisdiction.

     (k) Successors and Assigns. This Agreement shall be binding upon and inure
to the benefit of the parties and their respective successors and assigns,
including, to the extent provided below, purchasers of the Securities. The
Company shall not assign this Agreement or any rights or obligations hereunder
without the prior written consent of the holders of at least a majority of the
outstanding principal amount of the Notes including by merger or consolidation,
except pursuant to a Change of Control (as defined in the Notes) with respect to
which the Company is in compliance with the terms of the Notes. Other than in
connection with a sale pursuant to the Registration Rights Agreement, a Buyer
may assign some or all of its rights and obligations hereunder without the
consent of the Company; provided, however, that the transferee has agreed in
writing to be bound by the applicable provisions of this Agreement and provided,
further, that such assignment shall be in connection with a transfer of all or a
portion of the Notes and the Warrants held by such Buyer and subject to the
terms and conditions of the Notes and the Warrants, as applicable; and provided
further that, notwithstanding the foregoing, the representations, warranties and
indemnification obligation of the Company under this Agreement shall only be
made to and inure to the benefit of the initial Buyers and the Placement Agent.

     (l) [Reserved]

                                       30
<PAGE>
     (m) Publicity. The Company and the Placement Agent shall have the right to
approve before issuance any press releases or any other public statements with
respect to the transactions contemplated by the Transaction Documents; provided,
however, that neither the Company nor the Placement Agent shall have the right
to issue a press release referring to a Buyer or its affiliates without such
Buyer's prior written consent. The Placement Agent have the right to describe
their services to the Company in connection with the offering and to reproduce
the Company's name and logo in the Placement Agent's advertisements, marketing
materials and equity research reports, if any, in the form previously approved
by the Company and subject to the prior approval of the Company, which shall not
be unreasonably withheld, such additional uses as the Placement Agent may from
time to time request.

     (n) Termination. In the event that the Initial Closing shall not have
occurred with respect to a Buyer on or before five (5) Business Days from the
date hereof due to the Company's or such Buyer's failure to satisfy the
conditions set forth in Sections 6 and 7 of this Agreement (and the nonbreaching
party's failure to waive such unsatisfied conditions), the nonbreaching party
shall have the option to terminate this Agreement with respect to such breaching
party at the close of business on such date without liability of any party to
any other party, and the Company or the Placement Agent, as the case may be,
shall return any and all funds paid hereunder to the applicable Buyer no later
than the close of business on the Business Day following such termination;
provided, however, that if this Agreement is terminated pursuant to this Section
9(n), the Company shall remain obligated to reimburse any nonbreaching Buyer for
the expenses described in Section 4(i) of this Agreement.

     (o) Placement Agent. The Company acknowledges that it has engaged Piper
Jaffray & Co. (the "Placement Agent") as placement agent in connection with the
sale of the Notes and the Warrants and that the compensation of such agent is as
set forth on the Schedule of Fees attached hereto as Exhibit D. The Company
shall be responsible for the payment of any placement agent's fees, financial
advisory fees, or brokers' commissions (other than for persons engaged by any
Buyer or its investment advisor) relating to or arising out of the transactions
contemplated hereby. The Company shall pay, and hold each Buyer harmless
against, any liability, loss or expense (including, without limitation,
attorney's fees and out-of-pocket expenses) arising in connection with any such
claim.

     (p) Remedies. Each Buyer and each holder of the Securities shall have all
rights and remedies set forth in the Transaction Documents and all rights and
remedies which such holders have been granted at any time under any other
agreement or contract and all of the rights which such holders have under any
law. Any person having any rights under any provision of this Agreement shall be
entitled to enforce such rights specifically (without posting a bond or other
security), to recover damages by reason of any breach of any provision of this
Agreement and to exercise all other rights granted by law.

     (q) Payment Set Aside. To the extent that the Company makes a payment or
payments to any Buyer hereunder or pursuant to any of the other Transaction
Documents, or the Buyers enforce or exercise their rights hereunder or
thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be
fraudulent or preferential, set aside, recovered from, disgorged by or are
required to be refunded, repaid or otherwise restored to the Company, a trustee,
receiver or any other

                                       31
<PAGE>
person under any law (including, without limitation, any bankruptcy law, state
or federal law, common law or equitable cause of action), then to the extent of
any such restoration the obligation or part thereof originally intended to be
satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred.

                                       32
<PAGE>
     IN WITNESS WHEREOF, the parties have caused this Securities Purchase
Agreement to be duly executed as of the date first written above.

                                        "COMPANY"

                                        ATS MEDICAL, INC.

                                        By: /s/ John R. Judd
                                            ------------------------------------
                                        Its: Chief Financial Officer
                                             -----------------------------------

ACKNOWLEDGED AND AGREED:

"PLACEMENT AGENT"

PIPER JAFFRAY & CO.

By:  /s/ Eric Alt
     --------------------------------
Its: M.D. - CONVERTIBLE SECURITIES
     --------------------------------

                    [Signatures of Buyers on Following Page]

                                       33
<PAGE>
                [SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

                                        "BUYER"

                                        SF Capital Partners Ltd.
                                        ----------------------------------------
                                        (print full legal name of Buyer)

                                        By: /s/ Brian Davidson
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        Name: Brian Davidson
                                              ----------------------------------
                                        Its: Authorized Signatory
                                             -----------------------------------

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(A):

                                        By:
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        OR

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(B):

                                        By: /s/ Brian Davidson
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                       34
<PAGE>
              [SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

                                   "BUYER"

                                   Whitebox Convertible Arbitrage Partners, LP
                                   -------------------------------------------
                                   (print full legal name of Buyer)

                                   By: /s/ Andrew Redleaf
                                       ---------------------------------------
                                       (signature of authorized
                                        representative)

                                  Whitebox Convertible Arbitrage Partners, LP
                                    Whitebox Convertible Arbitrage Advisors LLC
                                      Whitebox Advisors LLC
                                        Andrew Redleaf, Managing Member of the
                                        General Partner

                                   Buyer hereby elects to be
                                   subject to Section 2(k)(A):

                                   By:
                                       ---------------------------------------
                                       (signature of authorized
                                        representative)

                                   OR

                                   Buyer hereby elects to be
                                   subject to Section 2(k)(B):

                                   By: /s/ Andrew Redleaf
                                       ---------------------------------------
                                       (signature of authorized
                                        representative)

                                  Whitebox Convertible Arbitrage Partners, LP
                                    Whitebox Convertible Arbitrage Advisors LLC
                                      Whitebox Advisors LLC
                                        Andrew Redleaf, Managing Member of the
                                        General Partner

                                       35

<PAGE>
                [SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

                                        "BUYER"

                                        Whitebox Intermarket Partners, LP
                                        ----------------------------------------
                                        (print full legal name of Buyer)

                                        By: /s/ Andrew Redleaf
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        Whitebox Intermarket Partners LP
                                           Whitebox Intermarket Advisors LLC
                                              Whitebox Advisors LLC
                                                Andrew Redleaf, Managing Member
                                                  of the General Partner

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(A):

                                        By:
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        OR

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(B):

                                        By: /s/ Andrew Redleaf
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        Whitebox Intermarket Partners LP
                                           Whitebox Intermarket Advisors LLC
                                              Whitebox Advisors LLC
                                                Andrew Redleaf, Managing Member
                                                  of the General Partner

                                       36
<PAGE>
                [SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

                                        "BUYER"

                                        HFR RVA Combined Master Trust
                                        ----------------------------------------
                                        (print full legal name of Buyer)

                                        By: /s/ Dora Hines
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        Name: Dora Hines
                                              ----------------------------------
                                        Its: for and on behalf of HFR Asset
                                             Management, LLC as attorney in fact
                                             -----------------------------------

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(A):

                                        By:
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        OR

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(B):

                                        By: /s/ Dora Hines
                                            ------------------------------------
                                            (signature of authorized
                                             representative)
                                             Dora Hines, for and on behalf of
                                             HFR Asset Management, LLC
                                             as attorney in fact

                                       37
<PAGE>
                [SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

                                        "BUYER"

                                        DBZ Acquisition Partners II, LLC
                                        ----------------------------------------
                                        (print full legal name of Buyer)

                                        By: /s/ David Proshan
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        Name: David Proshan
                                              ----------------------------------
                                        Its:  General Counsel
                                             -----------------------------------

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(A):

                                        By: /s/ David Proshan
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        OR

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(B):

                                        By:
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                       38
<PAGE>
                [SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

                                 "BUYER"

                                 The Northwestern Mutual Life Insurance Company
                                 ----------------------------------------------
                                 (print full legal name of Buyer)

                                 By: /s/ Richard A. Strait
                                    -------------------------------------------
                                    (signature of authorized
                                    representative)

                                 Name: Richard A. Strait
                                       ----------------------------------------
                                 Its: Authorized Representative
                                      -----------------------------------------

                                 Buyer hereby elects to be
                                 subject to Section 2(k)(A):

                                 By: /s/ Richard A. Strait
                                     -----------------------------------------
                                     (signature of authorized
                                      representative)

                                 OR

                                 Buyer hereby elects to be
                                 subject to Section 2(k)(B):

                                 By:
                                     -------------------------------------------
                                     (signature of authorized
                                      representative)

                                       39
<PAGE>
                [SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

                                    "BUYER"

                                    Radcliffe SPC, Ltd. for and on behalf of the
                                    Class A Convertible Crossover Segregated
                                    Portfolio

                                      By: RG Capital Management, L.P.

                                        By: RGC Management Company, L.L.C.

                                          By:  /s/ Gerald F. Stahlecker
                                             -------------------------------
                                             Managing Director

                                    Buyer hereby elects to be
                                    subject to Section 2(k)(A):

                                    By:
                                        ------------------------------------
                                        (signature of authorized
                                         representative)

                                    OR

                                    Buyer hereby elects to be
                                    subject to Section 2(k)(B):

                                    Radcliffe SPC, Ltd. for and on behalf of the
                                    Class A Convertible Crossover Segregated
                                    Portfolio

                                      By: RG Capital Management, L.P.

                                        By: RGC Management Company, L.L.C.

                                          By:  /s/ Gerald F. Stahlecker
                                             -------------------------------
                                             Managing Director

                                       40
<PAGE>
                [SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

                                        "BUYER"

                                        CAPITAL VENTURES INTERNATIONAL
                                        By: HEIGHTS CAPITAL MANAGEMENT, INC.,
                                            its authorized agent
                                        ----------------------------------------
                                        (print full legal name of Buyer)

                                        By: /s/ Martin Kobinger
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        Name: Martin Kobinger
                                              ----------------------------------
                                        Its: Investment Manager
                                             -----------------------------------

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(A):

                                        By:
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        OR

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(B):

                                        By: /s/ Martin Kobinger
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                       41
<PAGE>
                [SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

                                        "BUYER"

                                        Smithfield Fiduciary LLC
                                        ----------------------------------------
                                        (print full legal name of Buyer)

                                        By: /s/ Adam Chill
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        Name: Adam Chill
                                              ----------------------------------
                                        Its: Authorized Signatory
                                             -----------------------------------

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(A):

                                        By: /s/ Adam Chill
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                        OR

                                        Buyer hereby elects to be
                                        subject to Section 2(k)(B):

                                        By:
                                            ------------------------------------
                                            (signature of authorized
                                             representative)

                                       42
<PAGE>
                                    EXHIBIT A

                               SCHEDULE OF BUYERS

<TABLE>
<CAPTION>
                                                            DTC         PRINCIPAL     NUMBER OF
                     NAME OF BUYER                      PARTICIPANT     AMOUNT OF      INITIAL
             CONTACT INFORMATION FOR BUYER                 NUMBER     INITIAL NOTES    WARRANTS
             -----------------------------              -----------   -------------   ---------
<S>                                                     <C>           <C>             <C>
1. SF Capital Partners, Ltd.                                 352        $4,000,000     240,000
   3600 South Lake Drive
   St. Francis, WI 53235

2. Whitebox Entities:                                        214

      -   Whitebox Convertible Arbitrage Partners, LP                   $3,300,000     198,000
      -   Whitebox Intermarket Partners, LP                             $  500,000      30,000
      -   HFR RVA Combined Master Trust                                 $  200,000      12,000
   3033 Excelsior Boulevard, Suite 300
   Minneapolis, MN 55416

3. DBZ Acquisition Partners II, LLC                          005        $3,000,000     180,000
   745 Fifth Avenue, 18th Floor
   New York, NY 10151

4. The Northwestern Mutual Life                              954        $3,000,000     180,000
      Insurance Company
   720 East Wisconsin Avenue
   Milwaukee, WI 53202

5. Radcliffe SPC, Ltd. for and on behalf                     050        $2,500,000     150,000
      of the Class A Convertible Crossover
      Segregated Portfolio
   3 Bala Plaza East, Suite 501
   Bala Cynwyd, PA 19004

6. Capital Ventures International                           5198        $1,500,000      90,000
   101 California Street, Suite 3250
   San Francisco, CA 94111

7. Smithfield Fiduciary LLC                                  352        $1,000,000      60,000
   9 West 57th Street
   New York, NY 10019
</TABLE>
<PAGE>
                                    EXHIBIT B

                                FORM OF INDENTURE
<PAGE>
                                    EXHIBIT C

                         FORM OF WARRANT AGENT AGREEMENT
<PAGE>
                                    EXHIBIT D

                                SCHEDULE OF FEES

COMPENSATION:   6% of the aggregate principal amount of Notes issued by the
                Company
<PAGE>
                                    EXHIBIT E

                      FORM OF REGISTRATION RIGHTS AGREEMENT
<PAGE>
                                    EXHIBIT F

                 FORM OF IRREVOCABLE TRANSFER AGENT INSTRUCTIONS

October 7, 2005

VIA FEDERAL EXPRESS

Wells Fargo Shareowner Services
Compliance Department
161 North Concord Exchange
Saint Paul, Minnesota 55075

          Re: Reservation of Shares of Common Stock Pursuant to Sale by ATS
              Medical, Inc. of up to $23,750,000 in Aggregate Principal Amount
              of 6% Convertible Senior Notes due 2025 and Warrants to Purchase
              up to 1,425,000 Shares of Common Stock

Ladies and Gentlemen:

     ATS Medical, Inc., a Minnesota corporation (the "Company"), has agreed to
sell to the buyers listed on Schedule A hereto (the "Buyers"), on the date
hereof, Nineteen Million United States Dollars ($19,000,000) in aggregate
principal amount of 6% Convertible Senior Notes due 2025 (the "Notes"),
convertible into shares of the common stock, $0.01 par value per share (the
"Common Stock") of the Company, and warrants (the "Warrants") to purchase
1,140,000 shares of Common Stock, pursuant to that certain Securities Purchase
Agreement dated as of October 6, 2005, by and among the Company and each Buyer
(the "Securities Purchase Agreement"). Capitalized terms used herein without
definition have the meanings assigned to them in the Securities Purchase
Agreement.

     You are hereby instructed to:

     Establish as of the date of this letter a reserve of 286,972 shares of
Common Stock for issuance to holders of Notes upon conversion of their Notes
(the "Conversion Share Reserve"). The Conversion Share Reserve shall be adjusted
to appropriately reflect the filing of the Articles Amendment and the effect of
any stock split, reverse stock split, stock dividend (including any dividend or
distribution of securities convertible into Common Stock), reorganization,
recapitalization, reclassification, exchange or other like change with respect
to Common Stock occurring on or after the date hereof.

     Establish as of the date of this letter a reserve of 1,496,250 shares of
Common Stock for issuance to holders of Warrants upon exercise of their Warrants
(the "Warrant Share Reserve"). The Warrant Share Reserve shall be adjusted to
appropriately reflect the filing of the Articles Amendment and the effect of any
stock split, reverse stock split, stock dividend (including any dividend or
distribution of securities convertible into Common Stock), reorganization,
<PAGE>
recapitalization, reclassification, exchange or other like change with respect
to Common Stock occurring on or after the date hereof.

     A registration statement on Form S-3 to register the Common Stock issuable
out of the Conversion Share Reserve and the Warrant Share Reserve (the
"Registration Statement") will be filed with the Securities and Exchange
Commission (the "Commission") on or before November 6, 2005. We will forward to
you copies of the filing promptly after it is declared or deemed effective by
the Commission.

     Until the Registration Statement is declared effective by the Commission,
the certificates evidencing the shares of Common Stock issued out of the
Conversion Share Reserve or the Warrant Share Reserve will bear the restrictive
legend set forth below:

     THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
     UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR
     APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR
     SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE
     REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT AND
     APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION THEREFROM.

     So long as you have previously received (i) an opinion of the Company's
outside counsel (which the Company shall direct be delivered to you by such
outside counsel upon the effectiveness of the Registration Statement covering
the resales of the Common Stock) stating that a Registration Statement covering
the resales of the Common Stock has been declared effective by the Commission
under the Securities Act (the "Opinion"), (ii) a certification from the clearing
broker for the Buyers as to the fact that the sale of the Common Stock was made
in compliance with the Plan of Distribution set forth in the Registration
Statement (the "Broker Certification"), (iii) a copy of the Registration
Statement and (iv) confirmation from the Company that sales are permitted under
the Registration Statement at that time, the certificates representing the
Common Stock sold pursuant to the Registration Statement shall not bear any
legend restricting transfer of the Common Stock thereby and should not be
subject to any stop-transfer restriction.

     Without regard to whether or not a Registration Statement has ever been
declared effective with respect to the shares of Common Stock, so long as you
have previously received an opinion of the Company's outside counsel stating
that the shares have been sold pursuant to Rule 144 or stating that the shares
are eligible for resale pursuant to Rule 144(k), the certificates representing
such share of the Common Stock shall not bear any legend restricting transfer of
the Common Stock thereby and should not be subject to any stop-transfer
restriction.

     We enclose the following additional documents:

     A copy of the Securities Purchase Agreement; and
<PAGE>
     A capitalization table listing the Buyers and their respective beneficial
ownership interests in the Notes, the Warrants and any shares of Common Stock
issued pursuant thereto.

     Please be advised that the Buyers have relied upon this instruction letter
as an inducement to enter into the Securities Purchase Agreement and,
accordingly, each of the Buyers is a third party beneficiary to these
instructions.

     Please sign in the space provided below to evidence your acceptance and
acknowledgment of your responsibilities under this letter. Please call me at
(763) 557-2222 if you require any further information. Thank you for your
assistance.

                                        Very truly yours,

                                        ATS MEDICAL, INC.

                                        By:
                                            ------------------------------------
                                            John R. Judd, Chief Financial
                                            Officer

Acknowledged and Agreed:

WELLS FARGO BANK, NATIONAL
ASSOCIATION

By:
    ---------------------------------
Its:
     --------------------------------

cc: Mr. Eric Alt (w/o encl.)
Enclosures
<PAGE>
                                    EXHIBIT G

                         FORM OF COMPANY COUNSEL OPINION

     The Company is a corporation validly existing and in good standing under
the laws of the State of Minnesota, with corporate power to own its properties
and conduct its business as described in the Confidential Private Placement
Memorandum dated October 6, 2005, and to execute, deliver and perform its
obligations under the Transaction Documents.

     The execution, delivery and performance of the Transaction Documents have
been duly authorized by all requisite corporate action on the part of the
Company and the Transaction Documents have been duly executed and delivered by
the Company.

     The Transaction Documents constitute valid and binding obligations of the
Company, enforceable against the Company in accordance with their terms, except
(i) as rights to indemnification and contribution may be limited by federal or
state securities laws and policies underlying such laws and (ii) as such
enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium,
liquidation or similar laws relating to, or affecting generally, the enforcement
of creditors' rights and remedies.

     The execution and delivery by the Company of the Transaction Documents do
not, and the performance by the Company of its obligations under the Transaction
Documents will not, violate or conflict with the articles of incorporation or
bylaws of the Company or violate, breach or result in a default under any
agreement or instrument to which the Company is a party or by which it is bound
which would have to be filed as an exhibit to the Company's Form 10-K if the
Company was filing a Form 10-K for the first time as of the date hereof (the
"Listed Agreements").

     The execution and delivery by the Company of the Transaction Documents do
not, and the performance by the Company of its obligations under the Transaction
Documents will not, violate any judgment, order or decree known to us and
applicable to the Company of any court, governmental authority or arbitrator, or
violate any law of the United States, the State of New York or the State of
Minnesota, any rule or regulation of any governmental authority or regulatory
body of the United States, the State of New York or the State of Minnesota.

     The Notes and the Warrants have been duly authorized by all requisite
corporate action on the part of the Company and, upon payment for and upon
delivery of the Notes and the Warrants in accordance with the Securities
Purchase Agreement, the Notes and the Warrants will be validly issued free of
any preemptive rights or similar rights in the Listed Agreements.

     Except to the extent that Shareholder Approval (as defined in the
Securities Purchase Agreement) may be required to authorize and reserve all of
the Conversion Shares, the Conversion Shares have been duly authorized and
reserved for issuance upon conversion of the Notes by all requisite corporate
action on the part of the Company and, upon conversion of the Notes and delivery
of the Conversion Shares in accordance with the Notes, the Conversion
<PAGE>
Shares will be validly issued, fully paid and nonassessable and free of any
preemptive rights or similar rights in the Listed Agreements.

     The Warrant Shares have been duly authorized and reserved for issuance upon
exercise of the Warrants by all requisite corporate action on the part of the
Company and, upon payment of the exercise price upon exercise of the Warrants
and delivery of the Warrant Shares in accordance with the Warrants, the Warrant
Shares will be validly issued, fully paid, and nonassessable and free of any
preemptive rights or similar rights in the Listed Agreements.

     No order, consent, authorization or approval of any Minnesota, New York or
federal governmental authority or any third party under the Listed Agreements is
required to be obtained on the part of the Company for the execution and
delivery of, and performance of its obligations under, the Transaction Documents
except such as have been obtained and such as may be required under applicable
state and federal securities laws and regulations applicable to the offer and
sale of the Securities and by federal and state securities laws with respect to
the Company's obligations under the Registration Rights Agreement.

     Assuming the accuracy of your representations in Section 2 of the
Securities Purchase Agreement, no registration under the Securities Act, and no
qualification of the Indenture under the Trust Indenture Act, is required for
the purchase and sale of the Notes and the Warrants in the manner contemplated
by the Securities Purchase Agreement and the Confidential Private Placement
Memorandum.

     The SEC Documents incorporated by reference in the Confidential Private
Placement Memorandum, on the respective dates they were filed, appeared on their
face to comply in all material respects with the requirements as to form for
reports on Form 10-K, Form 10-Q, Form 8-K and Schedule 14A, except that we
express no opinion concerning the financial statements and other financial or
statistical information contained or incorporated by reference therein or the
exhibits thereto.
<PAGE>
                     FORM OF COMPANY COUNSEL 10B-5 STATEMENT

     In the course of acting as counsel for the Company in connection with the
preparation by the Placement Agent of the Confidential Private Placement
Memorandum dated October 6, 2005, we have participated in various discussions
and meetings with officers and other representatives of the Company,
representatives of the Company's independent registered public accounting firm,
and representatives of the Placement Agent and its counsel, at which time the
contents of the Confidential Private Placement Memorandum and related matters
were discussed. Although we cannot guarantee the accuracy and completeness of
the statements contained in the Confidential Private Placement Memorandum,
during the course of the above-described procedures, nothing came to our
attention that led us to believe that the Confidential Private Placement
Memorandum, as of the date thereof, contained an untrue statement of a material
fact or omitted to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading (provided that we express no view with
respect to the financial statements, the notes thereto and the related schedules
and other financial or statistical data included in the Confidential Private
Placement Memorandum).
<PAGE>
                                   SCHEDULE A

                            COMPANY WIRE INSTRUCTIONS

Please send all wires to ATS Medical, Inc. as follows:

Bank Name and Address: Silicon Valley Bank
                       3003 Tasman Drive, HF 195
                       Santa Clara, CA 95054

Routing #: __________
Acct. #:   __________
<PAGE>
                                  SCHEDULE 3(A)

                                  SUBSIDIARIES

*ATS Medical Sales, Inc., a Minnesota corporation

ATS Medical France, SARL, a French corporation

ATS Medical GmbH, a German corporation

The Subsidiary marked with an asterisk (*) is a Significant Subsidiary.
<PAGE>
                                  SCHEDULE 4(P)

                     BUYERS ELECTING SECTION 4(P) TREATMENT

-    SF Capital Partners, Ltd.
-    Whitebox Convertible Arbitrage Partners, LP
-    Whitebox Intermarket Partners, LP
-    HFR RVA Combined Master Trust
-    DBZ Acquisition Partners II, LLC
-    The Northwestern Mutual Life Insurance Company
-    Radcliffe SPC, Ltd. for and on behalf of the Class A Convertible Crossover
     Segregated Portfolio
-    Capital Ventures International
-    Smithfield Fiduciary LLC<PAGE>
                                                                  EXECUTION COPY

================================================================================

                                ATS MEDICAL, INC.

                                 as the Company

                                       and

                                     BUYERS,

                                as defined herein

                          REGISTRATION RIGHTS AGREEMENT

                           Dated as of October 7, 2005

================================================================================
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            Page
                                                                            ----
<S>                                                                         <C>
SECTION 1.    DEFINITIONS................................................     1
SECTION 2.    REGISTRATION...............................................     2
SECTION 3.    RELATED OBLIGATIONS........................................     6
SECTION 4.    OBLIGATIONS OF THE INVESTORS...............................    11
SECTION 5.    EXPENSES OF REGISTRATION...................................    11
SECTION 6.    INDEMNIFICATION............................................    12
SECTION 7.    CONTRIBUTION...............................................    15
SECTION 8.    REPORTING..................................................    15
SECTION 9.    ASSIGNMENT OF REGISTRATION RIGHTS..........................    16
SECTION 10.   AMENDMENT OF REGISTRATION RIGHTS...........................    16
SECTION 11.   MISCELLANEOUS..............................................    17
</TABLE>

                                    EXHIBITS

<TABLE>
<S>            <C>
Exhibit A...   Schedule of Buyers
</TABLE>

                                        i
<PAGE>
                          REGISTRATION RIGHTS AGREEMENT

     THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement"), is entered into as
of October 7, 2005, by and among ATS Medical, Inc., a Minnesota corporation (the
"Company"), and the buyers listed on the Schedule of Buyers attached hereto as
Exhibit A (each, a "Buyer" and, collectively, the "Buyers").

     THE PARTIES TO THIS AGREEMENT enter into this agreement on the basis of the
following facts, intentions and understanding:

     A. The Company and the Buyers entered into that certain Securities Purchase
Agreement of even date herewith (the "Securities Purchase Agreement"), and, upon
the terms and subject to the conditions of the Securities Purchase Agreement,
the Company has agreed to issue and sell to the Buyers an aggregate of up to
Twenty-Three Million Seven Hundred and Fifty Thousand United States Dollars
($23,750,000) of the Company's 6% Convertible Senior Notes due 2025 (such
Convertible Senior Notes, as the same may be amended, modified or supplemented
from time to time in accordance with the terms thereof, the "Notes"), which
shall be convertible into shares of common stock, $0.01 par value per share (the
"Common Stock") of the Company (as converted, the "Conversion Shares"), and
Warrants (such Warrants, as the same may be amended, modified or supplemented
from time to time in accordance with the terms thereof, the "Warrants") to
purchase up to One Million Four Hundred and Twenty-Five Thousand (1,425,000)
shares of Common Stock (as exercised, the "Warrant Shares").

     B. To induce the Buyers to execute and deliver the Securities Purchase
Agreement, the Company has agreed to provide certain registration rights to the
Buyers under the Securities Act of 1933, as amended, and the rules and
regulations thereunder, or any similar successor statute (collectively, the
"Securities Act"), and applicable state securities laws.

     NOW, THEREFORE, in consideration of the promises and the mutual covenants
contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company and each of the Buyers
hereby agree as follows:

     SECTION 1. DEFINITIONS. As used in this Agreement, the following terms
shall have the following meanings:

     (a) "Business Day" means any day other than Saturday, Sunday or any other
day on which commercial banks in The City of New York are required by law or
executive order to remain closed.

     (b) "Commission" means the Securities and Exchange Commission.

     (c) "Investor" means each Buyer and any transferee or assignee thereof to
whom a Buyer assigns its rights under this Agreement and who agrees to become
bound by the provisions of this Agreement in accordance with Section 9 of this
Agreement, and any subsequent transferee or assignee thereof to whom a
transferee or assignee assigns its rights under this Agreement and who agrees to
become bound by the provisions of this Agreement in accordance with Section 9 of
this Agreement.
<PAGE>
     (d) "Person" means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated
organization or association and governmental or any department or agency
thereof.

     (e) "register," "registered," and "registration" means a registration
effected by preparing and filing one or more Registration Statements (as defined
below) in compliance with the Securities Act and pursuant to Rule 415 under the
Securities Act or any successor rule providing for offering securities on a
continuous or delayed basis ("Rule 415"), and the declaration or ordering of
effectiveness of such Registration Statements by the Commission.

     (f) "Registrable Securities" means (i) the Notes, (ii) the Warrants, (iii)
the Conversion Shares issued or issuable upon conversion of the Notes, (iv) the
Warrant Shares issued or issuable upon exercise of the Warrants, (v) any shares
of capital stock issued or issuable with respect to the Conversion Shares or the
Warrant Shares as a result of any stock split, stock dividend, recapitalization,
exchange or similar event or otherwise, without regard to any limitations on
conversions of the Notes or the exercise of the Warrants, and (vi) any shares of
capital stock of any entity issued in respect of the securities referenced in
the immediately preceding clauses (i), (ii), (iii), (iv) and (v) as a result of
a merger, consolidation, sale of assets, sale or exchange of capital stock or
other similar transaction; provided, that any Registrable Securities that have
been sold pursuant to a Registration Statement or Rule 144 promulgated under the
Securities Act shall no longer be Registrable Securities.

     (g) "Registration Statement" means a registration statement or registration
statements of the Company filed under the Securities Act and, subject to Section
4(b), covering all of the Registrable Securities.

     (h) Capitalized terms used herein and not otherwise defined herein shall
have the respective meanings set forth in the Securities Purchase Agreement.

     SECTION 2. REGISTRATION.

     (a) Mandatory Registration. The Company shall prepare and, as soon as
practicable but in no event later than 30 calendar days after the Closing Date
and the Option Closing Date, if any, (as those terms are defined in the
Securities Purchase Agreement) (each a "Filing Deadline"), file with the
Commission a Registration Statement on Form S-3 covering the resale of all of
the Registrable Securities purchased on the Closing Date or Option Closing Date,
as the case may be. In the event that Form S-3 is unavailable for such a
registration, the Company shall use such other form as is available for such a
registration, subject to the provisions of Section 2(d) of this Agreement. Each
Registration Statement prepared pursuant hereto shall register the Registrable
Securities for resale, including at least 105% of the number of shares of Common
Stock issuable upon conversion of the Notes and exercise of the Warrants by the
Investors from time to time in accordance with the methods of distribution
elected by such Investors or such other amount as required by Section 4(e) of
the Securities Purchase Agreement. The Company shall use its best efforts to
have each Registration Statement declared effective by the Commission as soon as
practicable, but not later than 90 calendar days after the Closing Date or the
Option Closing Date, as the case may be, (each an "Effectiveness Deadline");
provided,

                                       2
<PAGE>
however, that if the Commission reviews a Registration Statement and requires
the Company to make modifications thereto, then the Effectiveness Deadline shall
be extended to 120 calendar days after the Closing Date. In the event that,
after the Closing Date or the Option Closing Date, as the case may be, and
before the related Registration Statement is declared effective, the offices of
the Commission are closed due to acts of God, war or terror, the Effectiveness
Deadline will be extended by a number of days equal to the days of any such
closure.

     (b) Allocation of Registrable Securities. The initial number of Conversion
Shares or Warrant Shares included in any Registration Statement and each
increase in the number of Conversion Shares and Warrant Shares included therein
shall be allocated pro rata among the Investors based on the number of
Conversion Shares and Warrant Shares covered by that Registration Statement
(determined as if all of the Notes held by Investors then outstanding have been
converted into Conversion Shares and all Warrants then outstanding have been
exercised for Warrant Shares, without regard to any limitations on conversion of
the Notes or exercise of the Warrants) held by each Investor at the time the
Registration Statement covering such initial number of Conversion Shares and
Warrant Shares or increase thereof is declared effective by the Commission. In
the event that an Investor sells or otherwise transfers any of such Investor's
Registrable Securities, each transferee shall be allocated the portion of the
then remaining number of Registrable Securities included in such Registration
Statement allocable to the transferor. In no event shall the Company include any
securities other than Registrable Securities on any Registration Statement
without the prior written consent of the Investors holding at least a majority
of the Conversion Shares and Warrant Shares covered by that Registration
Statement, determined as if all of the Notes held by Investors then outstanding
have been converted into Conversion Shares and all Warrants then outstanding
have been exercised for Warrant Shares without regard to any limitations on
conversion of the Notes or exercise of the Warrants.

     (c) Legal Counsel. Subject to Section 5 of this Agreement, the Investors
holding at least a majority of the Conversion Shares and Warrant Shares,
determined as if all of the Notes held by Investors then outstanding have been
converted into Conversion Shares and all Warrants then outstanding have been
exercised for Warrant Shares without regard to any limitations on conversion of
the Notes or on the exercise of the Warrants, shall have the right to select one
legal counsel to review and comment upon any registration pursuant to this
Agreement (the "Legal Counsel"), which counsel shall be designated in writing by
the holders of at least a majority of the Conversion Shares and Warrant Shares.
Such counsel designated in writing by the holders of at least a majority of the
Conversion Shares and Warrant Shares shall not represent any Investor that sends
such counsel written notice that such Investor does not wish such counsel to
represent it in connection with the matters discussed in this Section 2(c). The
Investors, other than any Investor that delivers the notice discussed in the
preceding sentence, hereby waive any conflict of interest or potential conflict
of interest that may arise as a result of the representation of such Investors
by such counsel in connection with the subject matter of this Agreement. The
provision will not prohibit any other counsel to an Investor from reviewing and
commenting on any registration filed pursuant to this Agreement at no cost to
the Company.

     (d) Ineligibility for Form S-3. If Form S-3 is not available for the
registration of the resale of the Registrable Securities hereunder or the
Company is not permitted by the Securities

                                       3
<PAGE>
Act or the Commission to use Form S-3, then the Company shall (i) register the
resale of the Registrable Securities on another appropriate form reasonably
acceptable to the holders of at least a majority of the Conversion Shares and
Warrant Shares to be registered on such Registration Statement, determined as if
all of the Notes held by Investors then outstanding have been converted into
Conversion Shares and all Warrants then outstanding have been exercised for
Warrant Shares without regard to any limitations on conversion of the Notes or
on the exercise of the Warrants, and (ii) undertake to register the Registrable
Securities on Form S-3 as soon as such form is available; provided, however,
that the Company shall maintain the effectiveness of the Registration Statement
then in effect until such time as a Registration Statement on Form S-3 covering
all of the Registrable Securities has been declared effective by the Commission
or, if earlier, until the end of the Registration Period (as defined in Section
3(a)).

     (e) Sufficient Number of Shares Registered. In the event the number of
Conversion Shares or Warrant Shares registered under a Registration Statement
filed pursuant to Section 2(a) of this Agreement is insufficient to cover all of
the Conversion Shares or Warrant Shares relating to that Registration Statement
or all of an Investor's allocated portion of the Conversion Shares or Warrant
Shares pursuant to Section 2(b) of this Agreement, the Company shall amend the
Registration Statement, or file a new Registration Statement (on the short form
available therefor, if applicable), or both, so as to cover at least one hundred
five percent (105%) of the number of such Conversion Shares or Warrant Shares as
of the trading day immediately preceding the date of the filing of such
amendment and/or new Registration Statement, in each case, as soon as
practicable, but in no event later than fifteen (15) days after the necessity
therefor arises. The Company shall use its best efforts to cause such amendment
and/or new Registration Statement to become effective as soon as practicable
following the filing thereof. The calculation of the number of shares sufficient
to cover all of the Conversion Shares or Warrant Shares shall be made without
regard to any limitations on the conversion of the Notes or the exercise of the
Warrants, and such calculation shall assume that all of the Notes are then
convertible into, and all the Warrants are then exercisable for, shares of
Common Stock at the then prevailing Conversion Price (as defined in the Notes)
or Exercise Price (as defined in the Warrants), as applicable. Notwithstanding
anything herein to the contrary, if the amendment to the Registration Statement
or new Registration Statement required by this Section 2(e) relates to a number
of Conversion Shares or Warrant Shares equal to or greater than ten percent
(10%) of the number of Conversion Shares or Warrant Shares as of the trading day
immediately preceding the date of the filing of such amendment and/or new
Registration Statement, such amendment or new Registration Statement shall be
declared effective by the Commission not later than 90 calendar days after the
filing date thereof; provided, however, that if the Commission reviews such
amendment or new Registration Statement and requires the Company to make
modifications thereto, then this deadline shall be extended to 120 calendar days
after the filing date. In the event that, after the Closing Date or the Option
Closing Date, as the case may be, and before the Registration Statement is
declared effective, the offices of the Commission are closed due to acts of God,
war or terror, this deadline will be extended by a number of days equal to the
days of any such closure.

     (f) Effect of Failure to File and Obtain and Maintain Effectiveness of
Registration Statement. Subject to any elections made pursuant to Section 4(b),
if (i) a Registration Statement covering all of the Registrable Securities
required to be covered by such Registration Statement

                                       4
<PAGE>
is not filed with the Commission on or before the Filing Deadline or is not
declared effective by the Commission on or before the Effectiveness Deadline,
(ii) a Registration Statement covering all of the Registrable Securities
required to be covered thereby, as described in Section 2(e) of this Agreement,
is not filed with the Commission on or before the deadline described in Section
2(e) of this Agreement or is not declared effective by the Commission on or
before the deadline described in Section 2(e) of this Agreement, (iii) the
Company fails to respond within 15 days to comments from the Commission
regarding a Registration Statement, (iv) a Registration Statement is not
declared effective within 10 days after receipt by the Company of a "no review"
letter from the Commission, (v) on any day after such Registration Statement has
been declared effective by the Commission, sales of all of the Registrable
Securities required to be included on such Registration Statement cannot be made
as a matter of law (other than during an Allowable Grace Period (as defined in
Section 3(o) of this Agreement)) pursuant to such Registration Statement
(including, without limitation, because of a failure to keep such Registration
Statement effective, to disclose such information as is necessary for sales to
be made pursuant to such Registration Statement or to register a sufficient
number of shares of Common Stock), (vi) the Company fails to maintain a
quotation or listing of its Common Stock on The New York Stock Exchange, Inc.,
the American Stock Exchange, Inc. or The Nasdaq National Market or SmallCap
Market, or (vii) a Grace Period (as defined in Section 3(o) of this Agreement)
exceeds the length of an Allowable Grace Period (each of the items described in
clauses (i) through (vi) above shall be referred to as a "Registration Delay"),
then the Company shall pay (1) to each holder of the Notes or Conversion Shares
covered by such Registration Statement an amount in cash equal to the product of
(i) the initial principal amount paid for the Note held by such holder or
related to the Conversion Shares held by such holder multiplied by (ii) the
product of (I) the percentage determined by dividing (A) the Applicable
Percentage by (B) 360, multiplied by (II) the sum of (x) the number of days
(including any partial days) after the Filing Deadline or the deadline described
in Section 2(e) of this Agreement, as applicable, that the Registration
Statement is not filed with the Commission, plus (y) the number of days
(including any partial days) after the Effectiveness Deadline or the deadline
described in Section 2(e) of this Agreement that the Registration Statement is
not declared effective by the Commission, plus (z) after the Registration
Statement has been declared effective by the Commission, the number of days
(including any partial days) that such Registration Statement is not available
(other than during an Allowable Grace Period) for the sale of all the
Registrable Securities, and (2) to each holder of the Warrants or Warrant Shares
covered by such Registration Statement an amount in cash equal to the product of
(i) the aggregate Exercise Price for such Warrant or paid for the related
Warrant Shares multiplied by (ii) the product of (I) the percentage determined
by dividing (A) the Applicable Percentage by (B) 360, multiplied by (II) the sum
of (x) the number of days (including any partial days) after the Filing Deadline
or the deadline described in Section 2(e) of this Agreement, as applicable, that
the Registration Statement is not filed with the Commission, plus (y) the number
of days (including any partial days) after the Effectiveness Deadline or the
deadline described in Section 2(e) of this Agreement, as applicable, that the
Registration Statement is not declared effective by the Commission, plus (z)
after the Registration Statement has been declared effective by the Commission,
the number of days (including any partial days) that such Registration Statement
is not available (other than during an Allowable Grace Period) for the sale of
all Registrable Securities. The "Applicable Percentage" shall mean (A) for
periods that only include days on or before the day that is 60 days after the
commencement of a Registration Delay, eight-tenths percent (0.8%), (B) for
periods that only include days after the

                                       5
<PAGE>
date that is 60 days after the commencement of a Registration Delay, one and
two-tenths percent (1.2%) and (C) for periods that include days both before and
after the date that is 60 days after the commencement of a Registration Delay, a
percentage equal to a fraction, the numerator of which shall be the sum of (i)
the number of days in such period that are on or before the date that is 60 days
after the commencement of such Registration Delay multiplied by eight-tenths
percent (0.8%) and (ii) the number of days in such period that are after the
date that is 60 days after the commencement of such Registration Delay
multiplied by one and two-tenths percent (1.2%) and the denominator of which
shall be the total number of days comprising such period. The payments to which
a holder shall be entitled pursuant to this Section 2(f) are referred to herein
as "Registration Delay Payments." The Registration Delay Payments shall be paid
in cash on the earlier of (A) the last day of the calendar month during which
such Registration Delay Payments are incurred and (B) the third Business Day
after the event or failure giving rise to the Registration Delay Payments is
cured. In the event the Company fails to make Registration Delay Payments in a
timely manner, such Registration Delay Payments shall bear interest at the rate
of one and six-tenths percent (1.6%) per month (prorated for partial months)
until paid in full.

     SECTION 3. RELATED OBLIGATIONS. At such time as the Company is obligated to
file a Registration Statement with the Commission pursuant to Section 2(a), 2(d)
or 2(e) of this Agreement, the Company will use reasonable best efforts to
effect the registration of all of the Registrable Securities required to be
covered by that Registration Statement in accordance with the intended method of
disposition thereof and, in connection with its obligations with respect to the
Registration Statement, the Company shall have the following obligations:

     (a) The Company shall promptly prepare and file with the Commission a
Registration Statement with respect to all of the Registrable Securities
required to be covered by that Registration Statement (but in no event later
than the applicable Filing Deadline) and use reasonable best efforts to cause
such Registration Statement relating to all of the Registrable Securities
required to be covered thereby to become effective as soon as practicable after
such filing (but in no event later than the applicable Effectiveness Deadline).
The Company shall, subject to the terms of this Agreement, keep each
Registration Statement effective pursuant to Rule 415 at all times during the
period from the date it is initially declared effective until the earliest of
(i) the second anniversary of the date such Registration Statement is filed,
(ii) the date as of which all of the Investors (other than any Investors who are
"affiliates" of the Company as such term is used in Rule 144(k) promulgated
under the Securities Act) may sell all of the Registrable Securities covered by
that Registration Statement without restriction pursuant to Rule 144(k) (or the
successor rule thereto) promulgated under the Securities Act, (iii) the date on
which all Registrable Securities covered by that Registration Statement have
been transferred under Rule 144 under circumstances in which all legends borne
by such Registrable Securities relating to restrictions on transferability
thereof, under the Securities Act or otherwise, are removed, or (iv) the date on
which all of the Investors shall have sold all of the Registrable Securities
covered by that Registration Statement (the "Registration Period") pursuant to a
Registration Statement, which Registration Statement, as of its filing and
effective dates and each day thereafter (including all amendments or supplements
thereto, as of their respective filing and effective dates and each day
thereafter), shall not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein, or necessary to make

                                       6
<PAGE>
the statements therein, not misleading, and the prospectus contained in such
Registration Statement, as of its filing date and each day thereafter (including
all amendments and supplements thereto, as of their respective filing dates and
each day thereafter), shall not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein, or necessary to
make the statements therein, in light of the circumstances in which they were
made, not misleading.

     (b) Subject to Section 3(o) of this Agreement, the Company shall prepare
and file with the Commission such amendments (including post-effective
amendments) and supplements to the Registration Statement and the prospectus
used in connection with such Registration Statement, which prospectus is to be
filed pursuant to Rule 424 (or any successor rule thereto) promulgated under the
Securities Act, as may be necessary to keep such Registration Statement
effective at all times during the Registration Period, and, during such period,
comply with the provisions of the Securities Act and respond within 15 days to
comments from the Commission regarding the Registration Statement. In the case
of amendments and supplements to a Registration Statement and the prospectus
used in connection with such Registration Statement which are required to be
filed pursuant to this Agreement (including pursuant to this Section 3(b)) by
reason of the Company filing a report on Form 10-K, Form 10-Q or Form 8-K or any
analogous report under the Securities Exchange Act of 1934, as amended, and the
rules and regulations thereunder, or any similar successor statute (the
"Exchange Act"), the Company shall have incorporated such report by reference
into such Registration Statement, if applicable, or shall file such amendments
or supplements with the Commission on the same day on which the Exchange Act
report is filed which created the requirement for the Company to amend or
supplement such Registration Statement and prospectus.

     (c) The Company shall permit Legal Counsel, or if no Legal Counsel shall
have been chosen by the Investors, the Investors and their respective legal
counsel, to review and provide written comment upon each Registration Statement,
prospectus and all amendments and supplements thereto at least three (3)
Business Days prior to their filing with the Commission. The Company shall
furnish to the Investors and Legal Counsel, without charge, (i) promptly after
receipt of such correspondence, copies of all correspondence from the Commission
or the staff of the Commission to the Company or its representatives relating to
each Registration Statement, prospectus and all amendments and supplements
thereto, (ii) promptly after the same is prepared and filed with the Commission,
one (1) copy of each Registration Statement, prospectus and all amendments and
supplements thereto, including all exhibits and financial statements related
thereto, and (iii) promptly upon the effectiveness of each Registration
Statement and each amendment and supplement thereto, one (1) copy of the
prospectus included in each such Registration Statement and all amendments and
supplements thereto. The Company agrees that it will, and it will cause its
counsel to, consider in good faith any comments or objections from Legal
Counsel, or if no Legal Counsel shall have been selected, the Investors and
their respective legal counsel, as to the form or content of each Registration
Statement, prospectus and all amendments or supplements thereto or any written
communications with the Commission or the staff of the Commission concerning a
Registration Statement, prospectus or any amendment or supplement thereto
including, without limitation, a request for acceleration of the effectiveness
of each Registration Statement, prospectus and all amendments or supplements
thereto.

                                       7
<PAGE>
     (d) The Company shall furnish to each Investor whose Registrable Securities
are included in any Registration Statement, without charge to such Investor, (i)
promptly after the same is prepared and filed with the Commission, at least one
copy of such Registration Statement and all amendments and supplements thereto,
including all exhibits and financial statements and each preliminary prospectus,
(ii) upon the effectiveness of each Registration Statement, such number of
copies of the prospectus included in such Registration Statement and all
amendments and supplements thereto as such Investor may reasonably request, and
(iii) such other documents, including copies of any preliminary or final
prospectus, as such Investor may reasonably request from time to time in order
to facilitate the disposition of the Registrable Securities.

     (e) Subject to Section 3(o) of this Agreement, and excluding any
Registrable Securities held by Investors electing to exclude their Registrable
Securities from the Registration Statement under Section 4(b), the Company shall
use reasonable best efforts to (i) promptly register and qualify, unless an
exemption from registration and qualification applies, the resale of the
Registrable Securities under such other securities or "blue sky" laws of all
applicable jurisdictions in the United States as any holder of Registrable
Securities reasonably requests in writing, (ii) promptly prepare and file in
those jurisdictions, such amendments (including post-effective amendments) and
supplements to such registrations and qualifications as may be necessary to
maintain the effectiveness thereof during the Registration Period, (iii)
promptly take such other actions as may be reasonably necessary to maintain such
registrations and qualifications in effect at all times during the Registration
Period, and (iv) promptly take all other actions reasonably necessary or
advisable to qualify the Registrable Securities for sale in such jurisdictions;
provided, however, that the Company shall not be required in connection
therewith or as a condition thereto to file a general consent to service of
process in any such jurisdiction, except in such jurisdictions where the Company
is subject to service of process. The Company shall promptly notify each
Investor who holds Registrable Securities and Legal Counsel of the receipt by
the Company of any notification with respect to the suspension of the
registration or qualification of any of the Registrable Securities for sale
under the securities or "blue sky" laws of any jurisdiction in the United States
or its receipt of notice of the initiation or threatening of any proceeding for
such purpose.

     (f) Notwithstanding anything to the contrary set forth herein, as promptly
as practicable after becoming aware of such event, the Company shall notify each
Investor and Legal Counsel in writing of the happening of any event as a result
of which (i) any Registration Statement or any amendment or supplement thereto,
as then in effect, includes an untrue statement of a material fact or omission
to state a material fact required to be stated therein or necessary to make the
statements therein not misleading or (ii) the prospectus related to such
Registration Statement or any amendment or supplement thereto includes an untrue
statement of a material fact or omission to state a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, and, subject to
Section 3(o) of this Agreement, promptly prepare a supplement or amendment to
such Registration Statement and prospectus to correct such untrue statement or
omission, and deliver such number of copies of such supplement or amendment to
each Investor and Legal Counsel as such Investor or Legal Counsel may reasonably
request. The Company shall also promptly notify each Investor and Legal Counsel
in writing (i) when a prospectus and

                                       8
<PAGE>
each prospectus supplement or amendment thereto has been filed, and when a
Registration Statement and each amendment (including post-effective amendments)
and supplement thereto has been declared effective by the Commission
(notification of such effectiveness shall be delivered to each Investor and
Legal Counsel by facsimile on the same day of such effectiveness and by
overnight mail), (ii) of any request by the Commission for amendments or
supplements to a Registration Statement or related prospectus or related
information or of receipt by the Company of any stop order from the Commission
relating to a Registration Statement, (iii) when the financial statements
included in a Registration Statement or related prospectus no longer satisfy the
requirements of such Registration Statement or prospectus and (iv) of the
Company's reasonable determination that an amendment (including any
post-effective amendment) or supplement to a Registration Statement or
prospectus would be appropriate (subject to Section 3(o) hereof).

     (g) Subject to Section 3(o) of this Agreement, the Company shall use
reasonable best efforts to (i) prevent the issuance of any stop order or other
suspension of effectiveness of a Registration Statement, or the suspension of
the qualification of any of the Registrable Securities for sale in any
jurisdiction, and (ii) if such an order or suspension is issued, obtain the
withdrawal of such order or suspension at the earliest practicable moment and
notify each holder of Registrable Securities and Legal Counsel of the issuance
of such order and the resolution thereof or its receipt of notice of the
initiation or threat of any proceeding for such purpose.

     (h) The Company shall hold in confidence and not make any disclosure of
information concerning an Investor provided to the Company unless (i) disclosure
of such information is necessary to comply with United States federal or state
securities laws, (ii) the disclosure of such information is necessary to avoid
or correct a misstatement or omission in any Registration Statement, prospectus
or any amendment or supplement thereto, (iii) the release of such information is
ordered pursuant to a subpoena or other final, non-appealable order from a court
or governmental body of competent jurisdiction, or (iv) such information has
been made generally available to the public other than by disclosure in
violation of this Agreement or any other agreement. The Company agrees that it
shall, upon learning that disclosure of such information concerning an Investor
is sought in or by a court or governmental body of competent jurisdiction or
through other means, unless ordered or requested by the Commission or other
governmental authority not to do so, give prompt written notice to such Investor
and allow such Investor, at the Investor's expense, to undertake appropriate
action to prevent disclosure of, or to obtain a protective order for, such
information.

     (i) The Company shall use reasonable best efforts to cause all the
Conversion Shares or Warrant Shares to be listed on each securities exchange or
automated quotation system on which securities of the same class or series
issued by the Company are then listed, if any, if the listing of such Conversion
Shares or Warrant Shares is then permitted under the rules of such exchange. The
Company shall pay all fees and expenses in connection with satisfying its
obligation under this Section 3(i).

     (j) The Company shall cause the Indenture to be qualified under the Trust
Indenture Act of 1939, as amended (the "TIA"), in connection with the
registration of the Registrable Securities, cooperate with the Trustee and the
Holders to effect such changes to the Indenture as

                                       9
<PAGE>
may be required for the Indenture to be so qualified in accordance with the
terms of the TIA and execute, and use their best efforts to cause the Trustee to
execute, all documents as may be required to effect such changes and all other
forms and documents required to be filed with the SEC to enable the Indenture to
be so qualified in a timely manner.

     (k) In connection with any sale or transfer of Registrable Securities
pursuant to a Registration Statement, the Company shall cooperate with the
Investors who hold Registrable Securities being offered and, to the extent
applicable, facilitate the timely preparation and delivery of certificates (not
bearing any restrictive legend) representing the Registrable Securities to be
offered pursuant to a Registration Statement and enable such certificates to be
in such denominations or amounts, as the case may be, as the Investors may
reasonably request and, registered in such names as the Investors may request.

     (l) If requested by an Investor, the Company shall (i) as soon as
practicable, incorporate in each prospectus supplement or post-effective
amendment to a Registration Statement such information as an Investor provides
in writing and reasonably requests to be included therein relating to the sale
and distribution of the Registrable Securities, and (ii) as soon as practicable,
make all required filings of such prospectus supplement or post-effective
amendment after being notified of the matters to be incorporated in such
prospectus supplement or post-effective amendment.

     (m) The Company shall comply with all applicable rules and regulations of
the Commission in connection with any registration hereunder.

     (n) Within one (1) Business Day after a Registration Statement is ordered
effective by the Commission, the Company will so notify the transfer agent for
the Registrable Securities and the Investors whose Registrable Securities are
included in the Registration Statement.

     (o) Notwithstanding anything to the contrary herein, at any time after a
Registration Statement has been declared effective by the Commission, the
Company may delay the disclosure of material non-public information concerning
the Company if the disclosure of such information at the time is not, in the
good faith judgment of the Board of Directors of the Company, in the best
interests of the Company (a "Grace Period"); provided, however, that the Company
shall promptly (i) notify the Investors in writing of the existence of material
non-public information giving rise to a Grace Period (provided that the Company
shall not disclose the content of such material non-public information to the
Investors) and the date on which the Grace Period will begin, and (ii) notify
the Investors in writing of the date on which the Grace Period ends; provided
further, that no single Grace Period shall exceed thirty (30) consecutive days,
and during any three hundred sixty-five (365) day period, the aggregate of all
of the Grace Periods relating to a single Registration Statement shall not
exceed an aggregate of sixty (60) days and the first day of any Grace Period
relating to a single Registration Statement must be at least ten (10) trading
days after the last day of any prior Grace Period relating to that Registration
Statement (each Grace Period complying with this provision being an "Allowable
Grace Period"). For purposes of determining the length of a Grace Period, the
Grace Period shall be deemed to begin on and include the date the Investors
receive the notice referred

                                       10
<PAGE>
to in clause (i) above and shall end on and include the later of the date the
Investors receive the notice referred to in clause (ii) above and the date
referred to in such notice; provided, however, that no Grace Period shall be
longer than an Allowable Grace Period. The provisions of Section 3(g) of this
Agreement shall not be applicable during the period of any Allowable Grace
Period. Upon expiration of the Grace Period, the Company shall again be bound by
the first sentence of Section 3(f) of this Agreement.

     (p) The Company shall supply to the Investors CUSIP numbers for the
Securities prior to effectiveness of the Registration Statement.

     SECTION 4. OBLIGATIONS OF THE INVESTORS.

     (a) At least five (5) Business Days prior to the first anticipated filing
date of a Registration Statement, the Company shall notify each Investor in
writing of the information the Company requires from each such Investor if such
Investor elects to have any of such Investor's Registrable Securities included
in such Registration Statement. It shall be a condition precedent to the
obligations of the Company to complete the registration pursuant to this
Agreement with respect to the Registrable Securities of a particular Investor
that such Investor shall furnish to the Company such information regarding
itself, the Registrable Securities held by it and the intended method of
disposition of the Registrable Securities held by it as shall be reasonably
required to effect the effectiveness of the registration of such Registrable
Securities and shall execute such documents in connection with such registration
as the Company may reasonably request. Each Investor shall promptly notify the
Company of any material change with respect to such information previously
provided to the Company by such Investor.

     (b) Each Investor agrees to cooperate with the Company as reasonably
requested by the Company in connection with the preparation and filing of any
Registration Statement hereunder, unless such Investor has notified the Company
in writing of such Investor's election to exclude all of such Investor's
Registrable Securities from such Registration Statement, in which case, such
Investor does not need to so cooperate with the Company until it notifies the
Company of its desire to include one or more shares of the Registrable
Securities in such Registration Statement.

     (c) Each Investor agrees that, upon receipt of any notice from the Company
of the happening of any event of the kind described in Section 3(g) or 3(o) of
this Agreement or the first sentence of Section 3(f) of this Agreement, such
Investor will immediately discontinue disposition of Registrable Securities
pursuant to any Registration Statements covering such Registrable Securities
until such Investor's receipt of the copies of the amended or supplemented
prospectus contemplated by Section 3(g) of this Agreement or the first sentence
of Section 3(f) of this Agreement or receipt of notice that no amendment or
supplement is required and, if so directed by the Company, such Investor shall
deliver to the Company (at the expense of the Company) or destroy (and deliver
to the Company a certificate of destruction) all copies of the prospectus
covering such Registrable Securities current at the time of receipt of such
notice (other than a single file copy, which such Investor may keep) in such
Investor's possession.

     SECTION 5. EXPENSES OF REGISTRATION. All expenses, other than underwriting
discounts and commissions, incurred in connection with registrations, filings or
qualifications

                                       11
<PAGE>
pursuant to Sections 2 and 3 of this Agreement, including, without limitation,
all registration, listing and qualifications fees, printers and accounting fees,
transfer agent fees and fees and disbursements of counsel for the Company, shall
be paid by the Company. The Company shall pay all fees and disbursements
relating to the qualification of the Indenture under the TIA. The Company shall
also reimburse the Investors for the fees and disbursements of Legal Counsel in
connection with registration, filing or qualification pursuant to Sections 2 and
3 of this Agreement which amount shall be limited to Ten Thousand United States
Dollars ($10,000) for each Registration Statement. The Company shall pay all of
the Investors' reasonable costs (including fees and disbursements of Legal
Counsel) incurred in connection with the successful enforcement of the
Investors' rights under this Agreement.

     SECTION 6. INDEMNIFICATION. In the event any Registrable Securities are
included in a Registration Statement under this Agreement:

     (a) To the fullest extent permitted by law, the Company will, and hereby
does, indemnify, hold harmless and defend each Investor, the directors,
officers, members, partners, employees, agents, and representatives thereof, and
each Person, if any, who controls any Investor within the meaning of the
Securities Act or the Exchange Act (each, an "Indemnified Person"), against any
losses, claims, damages, liabilities, judgments, fines, penalties, charges,
costs, reasonable attorneys' fees, amounts paid in settlement or expenses, joint
or several, (collectively, "Claims") incurred in investigating, preparing or
defending any action, claim, suit, inquiry, proceeding, investigation or appeal
taken from the foregoing by or before any court or governmental, administrative
or other regulatory agency, body or the Commission, whether pending or
threatened, whether or not an indemnified party is or may be a party thereto
("Indemnified Damages"), to which any of them may become subject insofar as such
Claims (or actions or proceedings, whether commenced or threatened, in respect
thereof) arise out of or are based upon (i) any untrue statement or alleged
untrue statement of a material fact in a Registration Statement or any amendment
(including post-effective amendments) or supplement thereto or in any filing
made in connection with the qualification of the offering under the securities
or other "blue sky" laws of any jurisdiction in which the Registrable Securities
are offered ("Blue Sky Filing"), or the omission or alleged omission to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading, (ii) any untrue statement or alleged untrue statement of
a material fact contained in any preliminary prospectus if authorized for use by
the Company prior to the effective date of such Registration Statement, or
contained in the final prospectus (as amended or supplemented, if any) or the
omission or alleged omission to state therein any material fact necessary to
make the statements made therein, in light of the circumstances under which the
statements therein were made, not misleading, (iii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act, any other law,
including, without limitation, any state securities law, or any rule or
regulation thereunder relating to the offer or sale of the Registrable
Securities pursuant to a Registration Statement, or (iv) any material violation
of this Agreement by the Company (the matters in the foregoing clauses (i)
through (iv) being, collectively, "Violations"). Subject to Section 6(c) of this
Agreement, the Company shall reimburse the Indemnified Persons, promptly as such
expenses are incurred and are due and payable, for any legal fees or other
reasonable expenses incurred by them in connection with investigating or
defending any such Claim. Notwithstanding anything to the contrary contained
herein, the indemnification agreement

                                       12
<PAGE>
contained in this Section 6(a) and the agreement with respect to contribution
contained in Section 7 of this Agreement: (i) shall not apply to a Claim by an
Indemnified Person arising out of or based upon a Violation which occurs in
reliance upon and in conformity with information furnished in writing to the
Company by such Indemnified Person or its legal counsel expressly for use in
connection with the preparation of the Registration Statement or any such
amendment thereof or supplement thereto; (ii) shall not be available to the
extent such Claim is based on a failure of the Investor to deliver or to cause
to be delivered the prospectus made available by the Company, including a
corrected prospectus, if such prospectus or corrected prospectus was timely made
available by the Company pursuant to Section 3(d) of this Agreement; and (iii)
shall not apply to amounts paid in settlement of any Claim if such settlement is
effected without the prior written consent of the Company, which consent shall
not be unreasonably withheld, conditioned or delayed. Such indemnity shall
remain in full force and effect regardless of any investigation made by or on
behalf of the Indemnified Person and shall survive the transfer of the
Registrable Securities by the Investors pursuant to Section 9 of this Agreement.

     (b) In connection with any Registration Statement in which an Investor is
participating, each such Investor agrees to severally and not jointly indemnify,
hold harmless and defend, to the same extent and in the same manner as is set
forth in Section 6(a) of this Agreement, the Company, each of its directors,
each of its officers who signs the Registration Statement, its agents and each
Person, if any, who controls the Company within the meaning of the Securities
Act or the Exchange Act (each, an "Indemnified Party"), against any Claims or
Indemnified Damages to which any of them may become subject, under the
Securities Act, the Exchange Act or otherwise, insofar as such Claims or
Indemnified Damages arise out of or are based upon any Violation (including for
purposes of this paragraph, a material violation of this Agreement by the
Investor), in each case to the extent, and only to the extent, that such
Violation occurs in reliance upon and in conformity with written information
furnished to the Company by such Investor or its legal counsel expressly for use
in connection with such Registration Statement and, subject to Section 6(c) of
this Agreement, such Investor will reimburse any legal or other expenses
reasonably incurred by an Indemnified Party in connection with investigating or
defending any such Claim; provided, however, that the indemnification agreement
contained in this Section 6(b) and the agreement with respect to contribution
contained in Section 7 of this Agreement shall not apply to amounts paid in
settlement of any Claim if such settlement is effected without the prior written
consent of such Investor, which consent shall not be unreasonably withheld or
delayed; provided, further, that the Investor shall be liable under this Section
6(b) for only that amount of the Claims and Indemnified Damages as does not
exceed the net proceeds to such Investors as a result of the sale of Registrable
Securities giving rise to such liability. Such indemnification agreement shall
remain in full force and effect regardless of any investigation made by or on
behalf of such Indemnified Party and shall survive the transfer of the
Registrable Securities by the Investors pursuant to Section 9 of this Agreement.
Notwithstanding anything to the contrary contained herein, the indemnification
agreement contained in this Section 6(b) shall not inure to the benefit of any
Indemnified Party if the untrue statement or omission of material fact contained
in the preliminary prospectus was corrected on a timely basis in the prospectus,
as then amended or supplemented.

     (c) Promptly after an Indemnified Person or Indemnified Party under this
Section 6 has knowledge of any Claim as to which such Indemnified Person or
Indemnified Party

                                       13
<PAGE>
reasonably believes indemnity may be sought or promptly after such Indemnified
Person or Indemnified Party receives notice of the commencement of any action or
proceeding (including any governmental action or proceeding) involving a Claim,
such Indemnified Person or Indemnified Party shall, if a Claim in respect
thereof is to be made against any indemnifying party under this Section 6,
deliver to the indemnifying party a written notice of such Claim, and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume control of the defense thereof with counsel
mutually satisfactory to the indemnifying party and the Indemnified Person or
the Indemnified Party, as the case may be; provided, however, that an
Indemnified Person or Indemnified Party shall have the right to retain its own
counsel if, in the reasonable opinion of counsel retained by the indemnifying
party, the representation by such counsel of the Indemnified Person or
Indemnified Party and the indemnifying party would be inappropriate due to
actual or potential differing interests between such Indemnified Person or
Indemnified Party and any other party represented by such counsel in such
proceeding; provided, further, that the indemnifying party shall not be
responsible for the reasonable fees and expense of more than one (1) separate
legal counsel for such Indemnified Person or Indemnified Party. In the case of
an Indemnified Person, the legal counsel referred to in the immediately
preceding sentence shall be selected by the Investors holding at least a
majority in interest of the Registrable Securities included in the Registration
Statement to which the Claim relates. The Indemnified Party or Indemnified
Person shall cooperate fully with the indemnifying party in connection with any
negotiation or defense of any such action or Claim by the indemnifying party and
shall furnish to the indemnifying party all information reasonably available to
the Indemnified Party or Indemnified Person which relates to such action or
Claim. The indemnifying party shall keep the Indemnified Party or Indemnified
Person fully apprised at all times as to the status of the defense or any
settlement negotiations with respect thereto. No indemnifying party shall be
liable for any settlement of any action, claim or proceeding effected without
its prior written consent; provided, however, that the indemnifying party shall
not unreasonably withhold, delay or condition its consent. No indemnifying party
shall, without the prior written consent of the Indemnified Party or Indemnified
Person, consent to entry of any judgment or enter into any settlement or other
compromise which does not include as an unconditional term thereof the giving by
the claimant or plaintiff to such Indemnified Party or Indemnified Person of a
full release from all liability in respect to such Claim and action and
proceeding. After indemnification as provided for under this Agreement, the
rights of the indemnifying party shall be subrogated to all rights of the
Indemnified Party or Indemnified Person with respect to all third parties, firms
or corporations relating to the matter for which indemnification has been made.
The failure to deliver written notice to the indemnifying party as provided in
this Agreement shall not relieve such indemnifying party of any liability to the
Indemnified Person or Indemnified Party under this Section 6, except to the
extent that the indemnifying party is prejudiced in its ability to defend such
action.

     (d) No Person involved in the sale of Registrable Securities who is guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) in connection with such sale shall be entitled to
indemnification from any Person involved in such sale of Registrable Securities
who is not guilty of fraudulent misrepresentation.

                                       14
<PAGE>
     (e) The indemnification required by this Section 6 shall be made by
periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred.

     (f) The indemnification agreements contained herein shall be in addition to
(i) any cause of action or similar right of the Indemnified Party or Indemnified
Person against the indemnifying party or others, and (ii) any liabilities the
indemnifying party may be subject to pursuant to the law.

     SECTION 7. CONTRIBUTION. If the indemnification provided for in Section 6
is held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any Claim referred to therein, then the indemnifying
party, in lieu of indemnifying such indemnified party hereunder, shall
contribute to the amount paid or payable by such indemnified party as a result
of such Claim in such proportion as is appropriate to reflect the relative fault
of the indemnifying party on the one hand and of the indemnified party on the
other in connection with the Violation that resulted in such Claims as well as
any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission to state a material fact relates to information
supplied by the indemnifying party or by the indemnified party and the parties'
relative intent, knowledge, access to information, and opportunity to correct or
prevent such statement or omission. Notwithstanding the foregoing, (i) no
contribution shall be made under circumstances where the maker would not have
been liable for indemnification under the fault standards set forth in Section 6
of this Agreement, (ii) no Person involved in the sale of Registrable Securities
who is guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) in connection with such sale shall be entitled to
contribution from any Person involved in such sale of Registrable Securities who
is not guilty of fraudulent misrepresentation, and (iii) contribution by any
seller of Registrable Securities shall be limited in amount to the dollar amount
of the proceeds (net of all expenses paid by such holder in connection with any
claim relating to Section 6 or this Section 7 and the amount of any damages such
holder has otherwise been required to pay by reason of such untrue or alleged
untrue statement or omission or alleged omission) received by it upon the sale
of the Registrable Securities giving rise to such contribution obligation. The
provisions of this Section 7 shall remain in full force and effect, regardless
of the investigation made by or on behalf of the beneficiaries of this Section 7
and shall survive the transfer of Registrable Securities by the Investors
pursuant to Section 9 of this Agreement.

     SECTION 8. REPORTING.

     (a) Reports Under The Exchange Act. With a view to making available to the
Investors the benefits of Rule 144 promulgated under the Securities Act or any
other similar rule or regulation of the Commission that may at any time permit
the Investors to sell securities of the Company to the public without
registration ("Rule 144"), for so long as Registrable Securities remain
outstanding, the Company shall use reasonable best efforts to:

                                       15
<PAGE>
     (1) make and keep public information available, as those terms are
understood and defined in Rule 144;

     (2) file with the Commission in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act;
and

     (3) furnish to each Investor, so long as such Investor owns Registrable
Securities, promptly upon request, (A) a written statement by the Company, if
true, that it has complied with the applicable reporting requirements of Rule
144, the Securities Act and the Exchange Act, (B) a copy of the most recent
annual or quarterly report of the Company and copies of such other reports and
documents so filed by the Company, and (C) such other information as may be
reasonably requested to permit the Investors to sell such securities pursuant to
Rule 144 without registration.

     (b) Rule 144A Information. The Company shall, for so long as Registrable
Securities remain outstanding, upon request of any Investor, for so long as such
Investor owns Registrable Securities, make available to such Investor the
information required by Rule 144A(d)(4) (or any successor rule) under the
Securities Act.

     SECTION 9. ASSIGNMENT OF REGISTRATION RIGHTS. The rights under this
Agreement shall be automatically assignable by the Investors to any transferee
of all or any portion of such Investor's Registrable Securities if: (i) the
Investor agrees in writing with the transferee or assignee to assign such
rights, and a copy of such agreement is furnished to the Company within a
reasonable time after such assignment; (ii) the Company is, within a reasonable
time after such transfer or assignment, furnished with written notice of (a) the
name and address of such transferee or assignee, and (b) the securities with
respect to which such rights are being transferred or assigned; (iii)
immediately following such transfer or assignment, the further disposition of
such securities by the transferee or assignee is restricted under the Securities
Act and applicable state securities laws; (iv) at or before the time the Company
receives the written notice contemplated by clause (ii) of this sentence, the
transferee or assignee agrees in writing with the Company to be bound by all of
the obligations of an Investor under this Agreement; (v) such transfer shall
have been made in accordance with the applicable requirements of the Securities
Purchase Agreement, the Indenture, the Notes, the Warrant Agent Agreement and
the Warrants; and (vi) such transfer shall have been conducted in accordance
with all applicable federal and state securities laws. With respect to any
transferee who fulfilled the foregoing obligations, the Company agrees to take
such actions as shall be necessary to permit such transferee to use the
Registration Statement and related prospectus, including, without limitation,
listing such transferee as a "selling shareholder" in the Registration Statement
and related prospectus.

     SECTION 10. AMENDMENT OF REGISTRATION RIGHTS. Any provision of this
Agreement may be amended and the observance of any provision of this Agreement
may be waived (either generally or in a particular instance and either
retroactively or prospectively), only with the written consent of the Company
and Investors who then hold at least a majority of the Conversion Shares and the
Warrant Shares, determined as if all of the Notes held by Investors then
outstanding have been converted into Conversion Shares and all Warrants then
outstanding

                                       16
<PAGE>
have been exercised for Warrant Shares without regard to any limitations on
conversion of the Notes or on the exercise of the Warrants. Any amendment or
waiver effected in accordance with this Section 10 shall be binding upon each
Investor and the Company. No such amendment shall be effective to the extent
that it applies to less than all of the holders of the Registrable Securities.
No consideration shall be offered or paid to any Person to amend or consent to a
waiver or modification of any provision of any of this Agreement unless the same
consideration also is offered to all of the parties to this Agreement.

     SECTION 11. MISCELLANEOUS.

     (a) A Person is deemed to be a holder of Registrable Securities whenever
such Person owns or is deemed to own of record such Registrable Securities. If
the Company receives conflicting instructions, notices or elections from two or
more Persons with respect to the same Registrable Securities, the Company shall
act upon the basis of instructions, notice or election received from such record
owner of such Registrable Securities.

     (b) Any notices, consents, waivers or other communications required or
permitted to be given under the terms of this Agreement must be in writing and
will be deemed to have been delivered: (i) upon receipt, when delivered
personally; (ii) upon receipt, when sent by facsimile (evidenced by mechanically
or electronically generated receipt by the sender's facsimile machine); or (iii)
one (1) Business Day after deposit with a nationally recognized overnight
delivery service, in each case properly addressed to the party to receive the
same. The addresses and facsimile numbers for such communications shall be:

     If to the Company:

          ATS Medical, Inc.
          3905 Annapolis Lane, Suite 105
          Minneapolis, Minnesota 55447
          Telephone: (763) 553-7736
          Facsimile: (763) 557-2244
          Attention: Mr. John R. Judd

     with a copy to:

          Dorsey & Whitney LLP
          50 South Sixth Street, Suite 1500
          Minneapolis, Minnesota 55402
          Telephone: (612) 340-2600
          Facsimile: (612) 340-2868
          Attention: Timothy S. Hearn, Esq.

     If to a Buyer, to its address and facsimile number set forth on the
     Schedule of Buyers attached hereto as Exhibit A, with copies to such
     Buyer's representatives as set forth on the Schedule of Buyers,

                                       17
<PAGE>
or to such other address and/or facsimile number and/or to the attention of such
other Person as the recipient party has specified by written notice given to
each other party. Written confirmation of receipt (A) given by the recipient of
such notice, consent, waiver or other communication, (B) mechanically or
electronically generated by the sender's facsimile machine containing the time,
date, recipient facsimile number and an image of the first page of such
transmission or (C) provided by a nationally recognized overnight delivery
service shall be rebuttable evidence of personal service, receipt by facsimile
or receipt from a nationally recognized overnight delivery service in accordance
with clause (i), (ii) or (iii) above, respectively.

     (c) Failure of any party to exercise any right or remedy under this
Agreement or otherwise, or delay by a party in exercising such right or remedy,
shall not operate as a waiver thereof.

     (d) All questions concerning the construction, validity, enforcement and
interpretation of this Agreement shall be governed by the internal laws of the
State of New York, without giving effect to any choice of law or conflict of law
provision or rule (whether of the State of New York or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the
State of New York. Each party hereby irrevocably submits to the non-exclusive
jurisdiction of the state and federal courts sitting the City of New York,
borough of Manhattan, for the adjudication of any dispute hereunder or in
connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such suit, action or proceeding is brought
in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by
mailing a copy thereof to such party at the address for such notices to it under
this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.
If any provision of this Agreement shall be invalid or unenforceable in any
jurisdiction, such invalidity or unenforceability shall not affect the validity
or enforceability of the remainder of this Agreement in that jurisdiction or the
validity or enforceability of any provision of this Agreement in any other
jurisdiction. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND
AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY
TRANSACTION CONTEMPLATED HEREBY.

     (e) This Agreement, the Securities Purchase Agreement, the Indenture, the
Notes, the Warrant Agent Agreement, the Warrants and the documents referenced
herein and therein constitute the entire agreement among the parties hereto with
respect to the subject matter hereof and thereof. There are no restrictions,
promises, warranties or undertakings, other than those set forth or referred to
herein and therein. This Agreement, the Securities Purchase Agreement, the
Indenture, the Notes, the Warrant Agent Agreement and the Warrants supersede all
prior

                                       18
<PAGE>
agreements and understandings among the parties hereto with respect to the
subject matter hereof and thereof.

     (f) Subject to the requirements of Section 9 of this Agreement, this
Agreement shall inure to the benefit of and be binding upon the permitted
successors and assigns of each of the parties hereto.

     (g) The headings in this Agreement are for convenience of reference only
and shall not limit or otherwise affect the meaning hereof.

     (h) This Agreement may be executed in identical counterparts, each of which
shall be deemed an original but all of which shall constitute one and the same
agreement. This Agreement, once executed by a party, may be delivered to the
other parties hereto by facsimile transmission of a copy of this Agreement
bearing the signature of the party so delivering this Agreement.

     (i) Each party shall do and perform, or cause to be done and performed, all
such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as the other party may
reasonably request in order to carry out the intent and accomplish the purposes
of this Agreement and the consummation of the transactions contemplated hereby.

     (j) All consents and other determinations required to be made by the
Investors pursuant to this Agreement shall be made, unless otherwise specified
in this Agreement, by Investors holding at least a majority of the Conversion
Shares and the Warrant Shares, determined as if all of the Notes held by
Investors then outstanding have been converted into Conversion Shares and all
Warrants then outstanding have been exercised for Warrant Shares without regard
to any limitations on conversion of the Notes or on the exercise of the
Warrants.

     (k) This Agreement is intended for the benefit of the parties hereto and
their respective permitted successors and assigns, and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person.

                                       19
<PAGE>
     IN WITNESS WHEREOF, the parties have caused this Registration Rights
Agreement to be duly executed as of day and year first above written.

                                        "COMPANY"

                                        ATS MEDICAL, INC.

                                        By: /s/ John R. Judd
                                            ------------------------------------
                                        Its: Chief Financial Officer
                                             -----------------------------------

                    [Signatures of Buyers on Following Page]

                                       20
<PAGE>
                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

                                        "BUYER"

                                                SF Capital Partners Ltd
                                        ---------------------------------------
                                            (print full legal name of Buyer)

                                        By: /s/ Brian Davidson
                                            ------------------------------------
                                            (signature of authorized
                                            representative)

                                        Name: Brian Davidson
                                              ----------------------------------
                                        Its:  Authorized Signatory
                                             -----------------------------------

                                       21
<PAGE>
                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

                                        "BUYER"

                              Whitebox Convertible Arbitrage Partners, LP
                           -------------------------------------------------
                                 (print full legal name of Buyer)

                           By: /s/ Andrew Redleaf
                               ---------------------------------------------
                               (signature of authorized
                               representative)

                                 Whitebox Convertible Arbitrage Partners, LP
                                     Whitebox Convertible Arbitrage Advisors LLC
                                            Whitebox Advisors LLC
                                                Andrew Redleaf, Managing Member
                                                of the General Partner

                                       22
<PAGE>
                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

                                        "BUYER"

                                        Whitebox Intermarket Partners, LP
                                   ---------------------------------------------
                                         (print full legal name of Buyer)

                               By: /s/ Andrew Redleaf
                                   ---------------------------------------------
                                   (signature of authorized
                                   representative)

                                     Whitebox Intermarket Partners, LP
                                         Whitebox Intermarket Advisors LLC
                                             Whitebox Advisors LLC
                                                 Andrew Redleaf, Managing Member
                                                 of the General Partner

                                       23
<PAGE>
                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

                                        "BUYER"

                                             HFR RVA Combined Master Trust
                                        ---------------------------------------
                                            (print full legal name of Buyer)

                                        By: /s/ Dora Hines
                                            ------------------------------------
                                            (signature of authorized
                                            representative)

                                        Name: Dora Hines
                                              ----------------------------------
                                        Its:  for and on behalf of
                                             -----------------------------------
                                              HFR Asset Management, LLC
                                              as attorney in fact

                                       24
<PAGE>
                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

                                        "BUYER"

                                           DBZ Acquisition Partners II, LLC
                                        ---------------------------------------
                                            (print full legal name of Buyer)

                                        By: /s/ David Proshan
                                            ------------------------------------
                                            (signature of authorized
                                            representative)

                                        Name: David Proshan
                                              ----------------------------------
                                        Its:  General Counsel
                                             -----------------------------------

                                       25
<PAGE>
                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

                                 "BUYER"

                                 THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY
                                 -----------------------------------------------
                                         (print full legal name of Buyer)

                                 By: /s/ Richard A. Strait
                                     -------------------------------------------
                                     (signature of authorized
                                     representative)

                                 Name: Richard A. Strait
                                     -------------------------------------------
                                 Its:  Authorized Representative
                                     -------------------------------------------

                                       26
<PAGE>
                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

                                        "BUYER"

                                        Radcliffe SPC, Ltd. for and on behalf of
                                        the Class A Convertible Crossover
                                        Segregated Portfolio

                                        By: RG Capital Management, L.P.

                                            By: RGC Management Company, L.L.C.

                                                By: /s/ Gerald F. Stahlecker
                                                    Managing Director

                                       27
<PAGE>
                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

                                        "BUYER"

                                        Capital Ventures International
                                        By: Heights Capital Management, Inc.
                                            its authorized agent
                                        ---------------------------------------
                                            (print full legal name of Buyer)

                                        By: /s/ Martin Kobinger
                                            ------------------------------------
                                            (signature of authorized
                                            representative)

                                        Name: Martin Kobinger
                                              ----------------------------------
                                        Its:  Investment Manager
                                             -----------------------------------

                                       28

<PAGE>
                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

                                        "BUYER"

                                               Smithfield Fiduciary LLC
                                        ---------------------------------------
                                            (print full legal name of Buyer)

                                        By: /s/ Adam Chill
                                            ------------------------------------
                                            (signature of authorized
                                            representative)

                                        Name: Adam Chill
                                              ----------------------------------
                                        Its:  Authorized Signatory
                                             -----------------------------------

                                       29
<PAGE>
                                    EXHIBIT A

                               SCHEDULE OF BUYERS

<TABLE>
<CAPTION>
                                              PRINCIPAL AMOUNT OF NOTES    NUMBER OF WARRANTS
               NAME OF BUYER                  -------------------------   --------------------
       CONTACT INFORMATION FOR BUYER             INITIAL    ADDITIONAL    INITIAL   ADDITIONAL
       -----------------------------           ----------   ----------    -------   ----------
<S>                                           <C>           <C>           <C>       <C>
1. SF Capital Partners, Ltd.                   $4,000,000   $1,000,000    240,000     60,000
   3600 South Lake Drive
   St. Francis, WI 53235

2. Whitebox Entities:
      -   Whitebox Convertible Arbitrage       $3,300,000   $  825,000    198,000     49,500
             Partners, LP
      -   Whitebox Intermarket Partners, LP    $  500,000   $  125,000     30,000      7,500
      -   HFR RVA Combined Master Trust        $  200,000   $   50,000     12,000      3,000
   3033 Excelsior Boulevard, Suite 300
   Minneapolis, MN 55416

3. DBZ Acquisition Partners II, LLC            $3,000,000   $  750,000    180,000     45,000
   745 Fifth Avenue, 18th Floor
   New York, NY 10151

4. The Northwestern Mutual Life                $3,000,000   $  750,000    180,000     45,000
      Insurance Company
   720 East Wisconsin Avenue
   Milwaukee, WI 53202

5. Radcliffe SPC, Ltd. for and on behalf       $2,500,000   $  625,000    150,000     37,500
      of the Class A Convertible Crossover
      Segregated Portfolio
   3 Bala Plaza East, Suite 501
   Bala Cynwyd, PA 19004

6. Capital Ventures International              $1,500,000   $  375,000     90,000     22,500
   101 California Street, Suite 3250
   San Francisco, CA 94111

7. Smithfield Fiduciary LLC                    $1,000,000   $  250,000     60,000     15,000
   9 West 57th Street
   New York, NY 10019
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]